Tranexamic acid for preventing postpartum haemorrhage by Cluver, Catherine Anne et al.
Cochrane Database of Systematic Reviews
Tranexamic acid for preventing postpartum haemorrhage
(Review)
Novikova N, Hofmeyr GJ, Cluver C
Novikova N, Hofmeyr GJ, Cluver C.
Tranexamic acid for preventing postpartumhaemorrhage.
Cochrane Database of Systematic Reviews 2015, Issue 6. Art. No.: CD007872.
DOI: 10.1002/14651858.CD007872.pub3.
www.cochranelibrary.com
Tranexamic acid for preventing postpartumhaemorrhage (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
5BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
18DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 1 Blood loss > 400 mL or > 500 mL. 47
Analysis 1.2. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 2 Blood loss > 1000 mL. . . . 48
Analysis 1.3. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 3 Mean blood loss (mL). . . . 49
Analysis 1.4. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 4 Use of additional medical
interventions to control PPH. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Analysis 1.5. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 5 Use of additional surgical
interventions to control PPH. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Analysis 1.6. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 6 Blood transfusion. . . . . 52
Analysis 1.7. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 7 Maternal death or severe maternal
morbidity such as seizure, thromboembolic events, need for intensive care unit admission, hysterectomy, organ
failure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Analysis 1.8. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 8 Side effects. . . . . . . 54
Analysis 1.9. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 9 Thromboembolic events. . . 55
Analysis 2.1. Comparison 2 Different doses of tranexamic acid, Outcome 1 Blood loss > 400 mL. . . . . . . . 56
Analysis 2.2. Comparison 2 Different doses of tranexamic acid, Outcome 2 Mean blood loss. . . . . . . . . 57
Analysis 2.3. Comparison 2 Different doses of tranexamic acid, Outcome 3 Use of additional medical interventions to
control PPH. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
Analysis 2.4. Comparison 2 Different doses of tranexamic acid, Outcome 4 Side effects. . . . . . . . . . . 58
Analysis 2.5. Comparison 2 Different doses of tranexamic acid, Outcome 5 Thromboembolic events. . . . . . . 59
59ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
60WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
62SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
62DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
62INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iTranexamic acid for preventing postpartum haemorrhage (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Tranexamic acid for preventing postpartum haemorrhage
Natalia Novikova1, G Justus Hofmeyr2, Catherine Cluver3
1Department of Obstetrics and Gynaecology, East London Hospital Complex, Walter Sisulu University, East London, South Africa.
2Department of Obstetrics and Gynaecology, East London Hospital Complex, University of the Witwatersrand, University of Fort
Hare, Eastern Cape Department of Health, East London, South Africa. 3Department of Obstetrics and Gynaecology, Faculty of Health
Sciences, Stellenbosch University and Tygerberg Hospital, Tygerberg, South Africa
Contact address: Natalia Novikova, Department of Obstetrics and Gynaecology, East London Hospital Complex, Walter Sisulu
University, Private Bag X9047, East London, 5200, South Africa. novikovanatalia@gmail.com.
Editorial group: Cochrane Pregnancy and Childbirth Group.
Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 6, 2015.
Citation: Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database of
Systematic Reviews 2015, Issue 6. Art. No.: CD007872. DOI: 10.1002/14651858.CD007872.pub3.
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Postpartum haemorrhage (PPH) is a common and potentially life-threatening complication of labour. Several options for preventing
PPH are available, but further advances in this field are important, especially the identification of safe, easy to use and cost-effective
regimens. Tranexamic acid (TA), which is an antifibrinolytic agent that is used widely to prevent and treat haemorrhage, merits
evaluation to assess whether it meets these criteria.
Objectives
To determine, from the best available evidence, whether TA is effective and safe for preventing PPH in comparison to placebo or no
treatment (with or without uterotonic co-treatment), or to uterotonic agents.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (28 January 2015) and reference lists of retrieved studies.
Selection criteria
All published, unpublished and ongoing randomised controlled trials (RCTs) evaluating the use of TA alone or in addition to uterotonics
in the third stage of labour or during caesarean section (CS) to prevent PPH.
Data collection and analysis
Two review authors independently assessed for inclusion all the potential studies identified as a result of the search strategy. We entered
the data into Review Manager software and checked for accuracy.
Main results
Twelve trials involving 3285 healthy women at low risk of excessive bleeding undergoing elective CS (nine trials, 2453 participants)
or spontaneous birth (three trials, 832 participants) satisfied inclusion criteria and contributed data to the analysis. All participants
received routine prophylactic uterotonics in accordance with the local guideline in addition to TA or placebo or no intervention. Overall,
included studies had moderate risk of bias for random sequence generation, allocation concealment, blinding, selective reporting and
low risk of bias for incomplete data. The quality of evidence was also as assessed using GRADE.
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Blood loss greater than 400 mL or 500 mL, and more than 1000 mL was less common in women who received TA versus placebo or
no intervention (risk ratio (RR) 0.52, 95% confidence interval (CI) 0.42 to 0.63, six trials, 1398 women; moderate quality evidence)
and (RR 0.40, 95% CI 0.23 to 0.71, six trials, 2093 women; moderate quality evidence), respectively. TA was effective in decreasing
the incidence of blood loss greater than 1000 mL in women who had undergone CS (RR 0.43, 95% CI 0.23, 0.78, four trials, 1534
women), but not vaginal birth (RR 0.28, 95% CI 0.06, 1.36, two trials 559 women). The effect of TA on blood loss greater than 500
mL or 400 mL was more pronounced in the group of women having vaginal birth than in women who had CS. Mean blood loss (from
delivery until two hours postpartum) was lower in women who received TA versus placebo or no intervention (mean difference MD -
77.79 mL, 95% CI -97.95, -57.64, five trials, 1186 women) and this effect was similar following vaginal birth and CS.
Additional medical interventions (moderate quality evidence) and blood transfusions were less frequent in women receiving TA versus
placebo or no interventions.Mild side effects such as nausea, vomiting, dizziness weremore commonwith the use of TA (moderate quality
evidence). The effect of TA on maternal mortality, severe morbidity and thromboembolic events is uncertain (low quality evidence).
Authors’ conclusions
TA (in addition to uterotonic medications) decreases postpartum blood loss and prevents PPH and blood transfusions following vaginal
birth and CS in women at low risk of PPH based on studies of mixed quality. There is insufficient evidence to draw conclusions about
serious side effects, but there is an increase in the incidence of minor side effects with the use of TA. Effects of TA on thromboembolic
events and mortality as well as its use in high-risk women should be investigated further.
P L A I N L A N G U A G E S U M M A R Y
Tranexamic acid for preventing bleeding after delivery
Postpartum haemorrhage is a common and an occasionally life-threatening complication of labour. The majority of women receive
drugs that directly stimulate the uterus (prophylactic uterotonics) during childbirth to prevent haemorrhages resulting from failure of
the uterine muscle to contract normally (uterine atony).
Tranexamic acid (TA) is used to decrease blood loss in surgery and health conditions associated with increased bleeding. It works by
helping to prevent the breakdown of fibrin and maintenance of blood clots. This review found that TA was also effective in reducing
excessive blood loss, need for additional medical interventions to control bleeding and blood transfusions after a mother gave birth
based on studies of mixed quality. Twelve trials (3285 participants) were included in the review. TA was given before caesarean section
in nine randomised trials or following the vaginal birth of a baby (three randomised trials) to generally healthy women.
TA decreased blood loss greater than 400 mL or greater than 500 mL and this effect was more apparent with vaginal births. The studies
had methodological shortcomings. Blood loss greater than 1000 mL decreased with the use of TA in six trials (2093 women), however,
the difference was most obvious in caesarean section (two trials, 1400 women) and not in vaginal birth in which there were few such
outcomes (one trial, 439 women). Mean blood loss decreased with the use of TA by 77 mL, overall (five studies, 1186 women) and
with both vaginal and caesarean section births. This finding was based on studies with methodological limitations.
The studies were too small to detect the effect of TA on maternal death or blood clots. Mild side effects, which include diarrhoea,
nausea and vomiting, were more common in women who received TA versus placebo or no intervention. No differences in blood loss
and side effects were found when two different doses of TA were evaluated. Further larger studies are needed to investigate the effects
of TA on maternal deaths and formation of clots in the blood (thromboembolism).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Tranexamic acid versus placebo/no treatment for preventing postpartum haemorrhage
Patient or population: pregnant women undergoing vaginal or caesarean birth who received TA for the prevent ion of postpartum haemorrhage
Settings: Studies were undertaken in China, India, Iran, Pakistan, Turkey
Intervention: Tranexamic acid versus placebo/ no treatment1
Outcomes Relative effect or Mean
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Blood loss > 400 mL or > 500 mL RR 0.52
(0.42 to 0.63)
1398
(6 studies)
⊕⊕⊕©
moderate2
- 2 studies reported an outcome blood
loss greater than 400 mL and 4 trials
greater than 500 mL
- 1 study invest igated 2 doses of
tranexamic acid, e.g. 0.5 g and 1 g and
we pooled the data for both groups in
this analysis
Blood loss > 1000 mL RR 0.40
(0.23 to 0.71)
2093
(6 studies)
⊕⊕⊕©
moderate3
Mean blood loss (mL) The mean blood loss in the inter-
vent ion groups was
- 77.79 lower
(- 97.95 to - 57.64)
1186
(5 studies)
⊕⊕⊕©
moderate 4
- 1 study invest igated two doses of
tranexamic acid, e.g. 0.5 g and 1 g and
we pooled the data for both groups in
this analysis
- 1 study was opened labelled.
Use of additional medical inter-
ventions to control PPH
RR 0.48
(0.34 to 0.68)
2049
(5 studies)
⊕⊕⊕©
moderate5
Maternal death or severe mater-
nal morbidity such as seizure,
thromboembolic events, need for
intensive care unit admission,
hysterectomy, organ failure
Not est imable 1511
(4 studies)
⊕⊕©©
low6
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Side effects RR 2.48 (1.36, 4.50) 2616
(8 studies)
⊕⊕⊕©
moderate7
Thromboembolic events RR 0.98
(0.14 to 6.78)
3012
(11 studies)
⊕⊕©©
low6
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Tranexamic acid was given by IV before caesarean birth or af ter vaginal birth in doses of 0.5 g or 10 mg/ kg and 1 g or 15
mg/ kg.
2 Downgraded for risk of bias (-1). One study had high risk of select ion bias; all f our studies had unclear risk of performance
and detect ion bias; one study had high risk and another study unclear risk of report ing bias.
3 Downgraded for risk of bias (-1). One trial used computer-generated numbers for randomisat ion, but the groups were
unequal, e.g. women in intervent ion group had BMI > 30, were anaemic and had longer t ime of surgery and more women in
control group had manual removal of placenta and more women in intervent ion group had placenta removed by controlled
cord tract ion. This trial also had unclear risk of select ive report ing bias. All three trials had unclear risk of performance bias
and detect ion bias.
4 Downgraded for risk of bias (- 1). One trial had unclear risk and one trial had high risk of select ion bias; two trials had
unclear risk and two trials had high risk of performance and detect ion bias; one trial had high risk of attrit ion bias, and three
trials had unclear risk of report ing bias.
5 Downgraded for risk of bias (-1). Two trials had high risk of allocat ion concealment and sequence generat ion bias. Three
trials had unclear risk of performance and detect ion bias.
6 Small sample size to detect this rare outcome (-1). Also downgraded for ROB (-1). One trial had high risk and one trial
had unclear risk of select ion bias; four trials had unclear risk of performance and detect ion bias; one trial had high risk and
another one unclear risk of report ing trials.
7 Downgraded (-1) for high stat ist ical heterogeneity (I² = 83%).
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B A C K G R O U N D
Description of the condition
Postpartum haemorrhage (PPH) remains a leading cause of mater-
nalmortality, especially in developing countries (Ronsmans 2006).
The majority (86%) of these deaths are preventable according
to the committee for confidential enquiries into maternal death
in South Africa (Confidential enquiries 2012). The incidence of
PPH according to a recent study is 1.2% (Sheldon 2014). Up to
75% of PPH cases are caused by uterine atony (Ducloy-Bouthors
2011), However, the cases of mortality due to obstetric haem-
orrhage are mainly related to other causes of PPH (Confidential
enquiries 2012). Uterine atony was found only in 6.4% of cases of
maternal death related to obstetric haemorrhage.Other conditions
such as abruption, placenta praevia, ruptured uterus, retained pla-
centa, morbidly adherent placenta, vaginal and cervical trauma,
inverted uterus, bleeding during and after caesarean section (CS)
are the cause of the vast majority of maternal deaths (Confidential
enquiries 2012). Considerable efforts to assure wide-spread access
to uterotonics have been successful and the majority of women re-
ceive prophylactic uterotonics during childbirth (Sheldon 2014).
Current alternatives to tranexamic acid (TA) in preventing PPH
include active management of the third stage of labour (involving
administration of a prophylactic oxytocic before delivery of the
placenta, and usually cord clamping and cutting, and controlled
traction of the umbilical cord, over passive management: allowing
the placenta to deliver spontaneously or aiding by gravity or nipple
stimulation), uterotonics and prostaglandins. Widely used active
management of labour is supported by a Cochrane review that
showed reduced incidence of PPH greater than 1000 mL with this
intervention (Begley 2015). However, assessment of individual
components of active management of labour failed to identify the
positive effects of early cord clamping on the amount of blood loss
and the incidence of PPH in another Cochrane review (McDonald
2013). Controlled cord traction in comparison to standard pla-
cental expulsion does not decrease the incidence of PPH, but has
a positive effect on the rate of retained placenta and intensity of
pain and discomfort in the third stage of labour (Deneux-Tharaux
2013). On the other hand, prophylactic oxytocin decreases the
incidence of PPH, therefore, it is the uterotonic component of
the active management of the third stage of labour that actually
prevents PPH. There is limited evidence to support the effect of
prophylactic oxytocin over ergot alkaloids on blood loss, but less
side effects are reported with oxytocin use versus ergot alkaloids.
There is no evidence supporting combined use of oxytocin and
ergot alkaloids. Oral or sublingual misoprostol is effective in re-
ducing the incidence of severe PPH when compared to placebo,
but is less effective than uterotonic agents Tunçalp 2012. How-
ever, the issue of maternal death due to PPH remains unresolved
in low-resource settings. Attempts to address the problem need to
go beyond the use of uterotonic drugs.
Description of the intervention
Tranexamic acid (TA) could be used in addition to current pro-
phylactic uterotonic drugs in the third stage of labour, particularly
in women at high risk of PPH, for example with placenta praevia,
placental abruption, anaemia, multiple pregnancy or CS. It is used
in the dose of 10 mg/kg given intravenously (IV) immediately af-
ter delivery of the baby (Astedt 1987) or in women undergoing
CS, prior to the skin incision or after delivery of the baby. TA acts
within two to three hours after oral administration and immedi-
ately after IV administration, and its half-life is two to 10 hours
(Jurema 2008). The oral route of administration is possible, but it
is not ideal in the third stage of labour, when an immediate effect
of the drug is required. The sublingual route may be an alternative,
but has not, to our knowledge, been investigated.
Prophylactic use of TA rather than waiting for a diagnosis of PPH
is supported by evidence from the CRASH-2 study which found
that TA was more effective the earlier it was administered in de-
creasing death due to bleeding in trauma patients (CRASH-2 trial
collaborators).
The use of TA acid for the treatment of PPH is covered by another
Cochrane review (Mousa 2014).
How the intervention might work
TA potentiates the blood clotting system and is used to treat and
prevent bleeding. The mechanism of action of TA is related to
its antifibrinolytic effect, which makes this drug potentially very
effective in the third stage of labour. TA is an inhibitor of fibri-
nolysis that blocks the lysine-binding site of plasminogen to fibrin
(Astedt 1987; Longstaff 1994). During placental delivery, rapid
degradation of fibrinogen and fibrin occurs, as well as an increase
in the activation of plasminogen activators and fibrin degradation
products due to activation of the fibrinolytic system. This activa-
tion can last up to six to 10 hours postpartum, which may cause
more haemorrhage. The antifibrinolytic effect of TA in the third
stage of labour could make it a safe and effective alternative or ad-
junct to other regimens currently used in the third stage of labour
for prevention of PPH.
TA could reduce blood loss associated with complications such as
placenta praevia and lower genital tract trauma, as well as bleeding
from the uterine body placental site. Use of TA could potentially
have prevented some PPH cases if it was given to women with risk
factors for PPH (Peitsidis 2011). Therefore, it may be particularly
useful in preventing cases of PPH due to factors other than uterine
atony, where uterotonic drugs would not be effective.
TA is an effective agent for the reduction of blood loss, which
has been widely used in various areas of medicine. It has been
used to decrease blood loss for many years in cases of haemor-
rhage, and is reported to reduce intraoperative and postoperative
blood loss (Boylan 1996; Karski 1995; Katsaros 1996; Reid 1997;
Vacharaksa 2002). TA is associated with a significant reduction in
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objective measurements of heavy menstrual bleeding when com-
pared to placebo or other medical therapies (non-steroidal antiin-
flammatory drugs (NSAIDS), oral luteal phase progestagens and
ethamsylate) according to a Cochrane review (Lethaby 2000).The
concerns regarding the side effects of tranexamic acid, and in par-
ticular, thromboembolic events are difficult to address because of
their rare occurrence and need for large trials to be able to explore
the issue adequately. TheCRASH-2 trial collaborators trial did not
assess the risk of thromboembolic events associated with TA. The
incidence of thromboembolic events was reported as low in a large
retrospective study assessing different postoperative prophylactic
anticoagulation regimens in patients with the use of TA undergo-
ing primary total hip and knee arthroplasty (Gillette 2013). Ker
and co-authors reported that effects of TA on thromboembolic
events was uncertain (deep vein thrombosis risk ratio (RR) 0.86,
95%confidence interval (CI) 0.52, 1.39 andpulmonary embolism
RR 0.61, 95% CI 0.25, 1.47) based on meta-analysis of 129 trials
involving 10,488 surgical patients (Ker 2012). A Cochrane review
on the use of antifibrinolytics for heavy menstrual bleeding re-
ported no rise in side effects with TA in comparison to placebo,
NSAIDS, oral luteal phase progestagens or ethamsylate (Lethaby
2000). The concerns regarding the risk of thromboembolic events
related to the use of TA are especially important when this drug is
used during the hypercoagulable state of pregnancy and the post-
partum period. The MEGA study found that the risk of throm-
boembolic events was increased five-fold during pregnancy and
increased 60-fold in the first three months after delivery compared
with non-pregnant women. Deep vein thrombosis of the leg had
a 14-fold increase and pulmonary embolism a six-fold increase in
pregnancy in this study Pomp 2008. Another large retrospective
trial reported the risk of venous thromboembolism to increase by
five-fold among pregnant or postpartumwomenHeit 2008. Three
cases of deep vein thrombosis were reported among 144 women
(two in the TA group and one in the control group) in a trial on
TA for treatment of PPH Ducloy-Bouthors 2011.
Why it is important to do this review
PPH remains an important cause of maternal morbidity and mor-
tality. It is important to establish safe, inexpensive and easily avail-
able methods of PPH prevention. Administration of TA IV in the
third stage of labour may be one of these methods. A particular
advantage of TA is that its effect is not limited to uterine body
placental site bleeding, thus, its use does not rely on accurate di-
agnosis of the site of the bleeding.
TA is a cost-effective drug. A study on total hip arthroplasty re-
ported saving blood transfusion and money (47 Euro per pa-
tient) in cases where TA was used prophylactically prior to surgery
(Johansson 2005). Using TA before CS may reduce the blood loss
as well.
Use of TA for preventing PPH may contribute to a reduction in
blood product use, which is associated with multiple risks (trans-
fusion reactions, transmission of blood-borne viruses), is expen-
sive and may be not available when it is needed. In low-resource
settings, most of the maternal deaths due to PPH occur in level
one hospitals or outside the hospital without any emergency access
to formal blood transfusion services. Cost savings could also be
gained from avoiding the use of expensive haematological agents
such as Factor VIIa, which is establishing its place in the treatment
of massive PPH in modern obstetrics in well-resourced settings
despite the extreme cost and limited evidence (Welsh 2008).
The side effects described with the use of TA include gastroin-
testinal symptoms such as diarrhoea, nausea and vomiting that
occur in about 10% of patients. Rare complications include hy-
potension, thrombosis, blurred vision, renal cortical necrosis and
retinal artery obstruction (Astedt 1987). A study by Becassy and
co-authors reported no side effects associated with TA (Bekassy
1990).
O B J E C T I V E S
To determine, from the best available evidence, whether tranex-
amic acid (TA) is effective and safe for preventing postpartum
haemorrhage (PPH) in comparison to placebo or uterotonic
agents.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all published, unpublished and ongoing randomised
controlled trials (RCTs) comparing the use of tranexamic acid (TA)
alone or in addition to uterotonics in the third stage of labour or
prior to or during caesarean section (CS) to prevent postpartum
haemorrhage (PPH).We excluded quasi-RCTs (for example, those
randomised by date of birth or hospital number or alternation)
from the analysis. We included studies published in abstract if they
satisfied other inclusion criteria.
Types of participants
Women undergoing vaginal or CS birth who received TA for pro-
phylaxis of PPH. TA is given immediately after delivery of the
baby following vaginal birth or in women undergoing CS, prior
to the skin incision.
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Types of interventions
Tranexamic acid used for the third stage of labour or at CS to
decrease blood loss compared with placebo or other agents such
as uterotonics; comparisons of TA dosages or routes of adminis-
tration.
Comparisons
1. TA versus placebo/no treatment
2. TA versus uterotonics
3. Different dosages of TA
4. Different routes of administration of TA
Types of outcome measures
Primary outcomes
1. Blood loss 500 mL or more
2. Blood loss 1000 mL or more
Secondary outcomes
3. Mean blood loss volume (mL)
4. Use of additional medical interventions to control PPH
5. Use of additional surgical interventions to control PPH
6. Blood transfusion (not prespecified)*
7. Maternal death or severe maternal morbidity such as seizure,
thromboembolic events, need for intensive care unit admission,
hysterectomy, organ failure
8. Mild side effects such as nausea, vomiting, headache, skin reac-
tions
9. Thromboembolic events
*Blood transfusion outcome was added in the current update of
the review instead of haemoglobin below 6 g%. Blood transfusion
was not included in the protocol and previously published version
of the review. The reason behind this change is the importance of
blood transfusion as an outcome when evaluating an intervention
for preventing haemorrhage. Blood transfusions are used in the
treatment of severe haemorrhage, they are costly, associated with
significant adverse reactions and may not be available in low-re-
source settings. Blood transfusion is an outcome assessed in other
Cochrane reviews on PPH (Mousa 2014; Tunçalp 2012;Westhoff
2013) and TA (Ker 2013; Perel 2013).
Themethods section of this review is based on a standard template
used by the Cochrane Pregnancy and Childbirth Group.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (28 Jan-
uary 2015).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL, the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
’Novikova 2010’.
For this update, the following methods were used for assessing the
20 reports that were identified as a result of the updated search.
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies we identified as a result of the search strategy. We
resolved any disagreement through discussion.
Data extraction and management
Wedesigned a form to extract data. For eligible studies, two review
authors (NN and CAC) extracted the data using the agreed form.
We resolved any discrepancies through discussion. NN entered
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the data into Review Manager software (RevMan 2014) and JH
checked them for accuracy.
When information regarding any of the above was unclear, we
attempted to contact the authors of the original reports to provide
further details.
In addition to the main outcomes and details on trial design, we
systematically extracted the following data for each study.
• Inclusion and exclusion criteria.
• Mode of delivery.
• Management of the third stage of labour.
• Duration and technique of assessment of blood loss.
• Missing data after randomisation.
Assessment of risk of bias in included studies
Two review authors independently assessed the validity of each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We resolved
any disagreement by discussion.
(1) Random sequence generation (checking for possible
selection bias)
We describe for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We describe for each included study the method used to conceal
allocation to interventions prior to assignment and assess whether
intervention allocation could have been foreseen in advance of, or
during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3) Blinding of participants, personnel and outcome
assessors (checking for possible performance bias)
We describe for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered studies to be at
low risk of bias if they were blinded, or if we judge that the lack of
blinding would be unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel;
• low, high or unclear risk of bias for outcome assessors.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We describe for each included study, and for each outcome or class
of outcomes, the completeness of data including attrition and ex-
clusions from the analysis. We state whether attrition and exclu-
sions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or was supplied by the
trial authors, we re-included missing data in the analyses which
we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We describe for each included study how we investigated the pos-
sibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We describe for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
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• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to (1) to (6) above, we assessed
the likely magnitude and direction of the bias and whether we
considered it likely to impact on the findings. We explored the
impact of the level of bias through undertaking sensitivity analyses
- see Sensitivity analysis.
Assessment of quality of evidence
For this update the quality of the evidence was assessed using
the GRADE approach (Schunemann 2009) in order to assess the
quality of the body of evidence relating to the following outcomes
for the main comparison:
1. Blood loss 500 mL or more
2. Blood loss 1000 mL or more
3. Mean blood loss volume (mL)
4. Use of additional medical interventions to control PPH
5. Maternal death or severe maternal morbidity such as
seizure, thromboembolic events, need for intensive care unit
admission, hysterectomy, organ failure
6. Mild side effects such as nausea, vomiting, headache, skin
reactions
7. Thromboembolic events
GRADEprofiler (GRADEpro2014)was used to import data from
Review Manager 5.3 (RevMan 2014) in order to create ’Summary
of findings’ tables. A summary of the intervention effect and a
measure of quality for each of the above outcomes was produced
using theGRADE approach. TheGRADE approach uses five con-
siderations (study limitations, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality of the body
of evidence for each outcome. The evidence can be downgraded
from ’high quality’ by one level for serious (or by two levels for very
serious) limitations, depending on assessments for risk of bias, in-
directness of evidence, serious inconsistency, imprecision of effect
estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
(RR) with 95% confidence intervals (CI).
Continuous data
For continuous data, we used the mean difference (MD) as the
outcomes were measured in the same way in both trials.
In future updates of this review, we will use the standardised mean
difference to combine trials that measure the same outcome, but
use different methods.
Unit of analysis issues
Cluster-randomised trials
If, in future updates of this review, we identify cluster-randomised
trials for inclusion, we will include them in the analyses along with
individually-randomised trials. We will adjust their sample sizes
using the methods described in the Handbook using an estimate
of the intra-cluster correlation co-efficient (ICC) derived from
the trial (if possible), from a similar trial or from a study of a
similar population. If we use ICCs from other sources, we will
report this and conduct sensitivity analyses to investigate the effect
of variation in the ICC. If we identify both cluster-randomised
trials and individually-randomised trials, we plan to synthesise the
relevant information. We will consider it reasonable to combine
the results from both if there is little heterogeneity between the
study designs and the interactionbetween the effect of intervention
and the choice of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a subgroup analysis to investigate the effects of the
randomisation unit.
Cross-over trials
Cross-over trials are irrelevant for this intervention, and, therefore
we have not included them.
Multi-armed trials
When analysing multi-armed trials, we combined all relevant ex-
perimental intervention groups of the study into a single group
and all relevant control intervention groups into a single control
group. If the authors considered one of the arms irrelevant, we
excluded it from analysis.
For dichotomous outcomes, both the sample sizes and the num-
bers of people with events were added from all groups. For con-
tinuous outcomes, means and standard deviations were calculated
using a formula available in Table 7.7.a in Chapter 7.7.3.8 in the
Handbook (Higgins 2011).
Dealing with missing data
For included studies, we noted levels of attrition. We planned to
explore the impact of including studies with high levels of missing
data in the overall assessment of treatment effect by using sensi-
tivity analysis.
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For all outcomes, we carried out analyses, as far as possible, on an
intention-to-treat basis, i.e. we attempted to include all partici-
pants randomised to each group in the analyses, and to analyse all
participants in the group to which they were allocated, regardless
of whether or not they received the allocated intervention. The
denominator for each outcome in each trial was the number ran-
domised minus any participants whose outcomes were known to
be missing.
Assessment of heterogeneity
We used the Tau², I² and Chi² statistics to measure heterogeneity
among the trials in each analysis. We regarded heterogeneity as
substantial if an I² was greater than 30% and either a Tau² was
greater than zero, or there was a low P value (less than 0.10) in the
Chi² test for heterogeneity.
Assessment of reporting biases
We planned to assess reporting biases if 10 or more studies were
included in the meta-analysis. In this update (2015), only two
meta-analyses included more than 10 studies. In future updates,
if more studies are included, we will investigate reporting biases
(such as publication bias) using funnel plots.We will visually assess
funnel plot asymmetry.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar.
If there was clinical heterogeneity sufficient to expect that the un-
derlying treatment effects differed between trials, or if substan-
tial statistical heterogeneity was detected, we used random-effects
meta-analysis to produce an overall summary if an average treat-
ment effect across trials was considered clinically meaningful. The
random-effects summary was treated as the average of the range of
possible treatment effects and we discuss the clinical implications
of treatment effects differing between trials. If the average treat-
ment effect was not considered clinically meaningful, we planned
not to combine trials. If we used random-effects analyses, the re-
sults were presented as the average treatment effect with 95% con-
fidence intervals, and the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
For analyses with substantial heterogeneity we performed random-
effects analysis and sensitivity analyses.
We assessed the following subgroup for all outcomes:
• women undergoing vaginal birth versus CS.
We plan to assess primary outcomes for following subgroup in the
future updates of the review if the data become available:
• women who received versus women who did not receive
routine uterotonics.
We compared all outcomes in subgroup “vaginal birth versus CS”
because of potential differences in these two modes of birth. The
secondary outcomes (for example, thromboembolic events) are in-
cluded in the subgroup analysis because of its potential association
with the use of TA, which is especially important in women un-
dergoing CS because their risk of thromboembolic events is higher
than in women with vaginal birth.
We planned to assess subgroup differences by interaction tests
available within RevMan (RevMan 2014) and report the results
of subgroup analyses quoting the Chi² statistic and P value, and
the interaction test I² value.
Sensitivity analysis
We performed sensitivity analyses for aspects of the review that
might have affected the results, for example where there is a risk
of bias associated with the quality of some of the included trials;
or to explore the effects of fixed-effect or random-effects analyses
for outcomes with statistical heterogeneity.
We planned to perform sensitivity analysis for the primary out-
comes (blood loss greater than 500 mL and greater than 1000
mL).
We performed sensitivity analysis for primary outcomes by ex-
cluding the trials that did not use placebo.
R E S U L T S
Description of studies
Results of the search
The search retrieved 24 new reports of 22 trials. Three trials are
still ongoing (Farber 2013; Shirazi 2012; Sentilhes 2014).We have
added10 studies (Abdel-Aleem2013;Goswami 2013;Gungorduk
2011; Gungorduk 2013; Mirghafourvand 2013; Movafegh 2011;
Senturk 2013; Shahid 2013; Xu 2013, Yehia 2014) to the two
previously included trials (Gai 2004; Yang 2001). Two trials are
awaiting classification published in abstract form Bhavana 2013,
Ahmed 2014 and the information in the abstracts is not sufficient
for appraisal. We have excluded two newly identified trials (Halder
2013; Tarabrin 2012) in addition to the previously excluded three
studies (Gobbur 2011; Gohel 2007; Sekhavat 2009).
This updated review now comprises 12 included, five excluded,
three ongoing and two awaiting classification trials. Data from 12
trials (3285 participants) contributed to this meta-analysis (Figure
1).
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Figure 1. Study flow diagram
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For further details see Characteristics of included studies and
Characteristics of excluded studies.
Included studies
TA for vaginal birth
We included three trials (Gungorduk 2013; Mirghafourvand
2013; Yang 2001) from Turkey, Iran and China, respectively in-
vestigating the efficacy and safety of TA for preventing postpartum
haemorrhage (PPH) in eight hundred thirty two women who had
vaginal birth.
TA for CS
We included nine trials (2453 participants) investigating the effi-
cacy of TA in reducing blood loss during CS undertaken in Egypt
(Abdel-Aleem2013, Yehia 2014); China (Gai 2004, Xu 2013); In-
dia (Goswami 2013); Turkey (Gungorduk 2011; Senturk 2013);
Iran (Movafegh 2011), Pakistan (Shahid 2013).
One trial included women with anaemia defined by the authors as
haemoglobin between 7% and 10g% (Goswami 2013). The rest
of trials’ participants were low-risk women undergoing elective CS
under spinal or epidural anaesthesia who were allocated to receive
either TA or placebo.
Timing of administration of intervention
TA was administered at different times in the trials:
• some time (unspecified) before commencement of CS
(Abdel-Aleem 2013; Goswami 2013);
• at the time of induction of anaesthesia (Yehia 2014);
• 10 minutes before skin incision (Gai 2004; Gungorduk
2011; Shahid 2013);
• 20 minutes before commencement of spinal anaesthesia
(Movafegh 2011);
• 10 minutes before anaesthesia (Senturk 2013);
• 20 minutes after beginning of anaesthesia (Xu 2013).
Dose of TA
Six trials used one g ofTAdiluted in 20mLof 5%glucose, given IV
over fiveminutes (Gai 2004; Gungorduk 2011; Gungorduk 2013;
Mirghafourvand 2013; Senturk 2013) and two trials the same
dose given over 10 minutes (Abdel-Aleem 2013; Shahid 2013).
One trial used 1G of TA by slow intravenous injection (Yehia
2014). Two trials used 10 mg/kg TA IV in 200 mL of normal
saline infused over 10 minutes (Movafegh 2011; Xu 2013). One
trial used TA 10 mg/kg in 20 mL of 5% dextrose in one group
and 15 mg/kg in another group diluted in 20 mL of 5% glucose
given over 20 minutes (Goswami 2013). The latter trial included
women with average weight of 57 kg, therefore, women received
TA in an average dose of 0.6 g in one group and 0.9 g in the other
group. One trial compared 0.5 g and 1 g TA given intravenously
2-3 minutes following delivery of the baby Yang 2001. When two
different doses (0.5 g or 10 mg/kg and 1 g or 15mg/kg) (Goswami
2013; Yang 2001) were compared to each other and to placebo we
have combined the treatment groups in the analysis as described
above.
Comparisons
TA was compared to placebo (normal saline or dextrose solu-
tion) in all Goswami 2013; Gungorduk 2011; Gungorduk 2013;
Mirghafourvand 2013; Movafegh 2011; Senturk 2013; Shahid
2013; Xu 2013, except four trials Abdel-Aleem 2013; Gai 2004;
Yang 2001; Yehia 2014 which compared TA to no intervention.
All studies used various regimes of routine prophylactic uterotonic
agents administered to all participants:
• Abdel-Aleem 2013 used 5 IU (international units) oxytocin
bolus intravenously and 20 IU oxytocin intravenous infusion;
• Gai 2004 administered 10 IU oxytocin intravenously and
20 units into the uterine wall simultaneously after delivery of the
baby;
• Goswami 2013 used 20 IU oxytocin in 500 mL of normal
saline intravenously over four hours;
• Gungorduk 2011; Gungorduk 2013 used 5 IU oxytocin
bolus and 30 IU oxytocin in 500 mL of Ringer’s lactate over four
hours after delivery of the baby;
• Mirghafourvand 2013 used 10 IU oxytocin in 500 mL of
normal saline over 20 minutes intravenously after delivery of the
placenta;
• Movafegh 2011 used 10 IU oxytocin in 500 mL of normal
saline over 20 minutes after delivery of the baby, followed by 30
IU oxytocin over eight hours;
• Senturk 2013 used 20 IU oxytocin intravenously bolus after
removal of the placenta;
• Shahid 2013 used 5 IU oxytocin intravenous bolus and 0.4
mg methylergometrine intravenously and 30 IU oxytocin in 500
mL Ringer’s lactate over six hours;
• Xu 2013 used 10 IU oxytocin in a pint of dextrose normal
saline intravenously over 30 minutes;
• Yang 2001; Yehia 2014 used 10 IU oxytocin intravenously
immediately post the baby delivery.
Outcomes
The majority of included studies contributed data only on a few
outcomes (Table 1).
All trials exceptGungorduk 2011 used a standardmethod of blood
loss calculation using a formula = all used materials’ weight within
2 hours postpartum plus unused materials weight minus materials
weight before used)/1.05 plus directly collected blood volume.
The Gungorduk 2011 trial used preoperative and postoperative
haematocrit levels for estimation of blood loss and we did not
include the results in the meta-analysis.
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Meanblood loss volume in vaginal birthwasmeasured byweighing
a sheet soaked from the end of the delivery till 2 hours after birth
all trials (Gungorduk 2013; Mirghafourvand 2013; Yang 2001).
Mean blood loss following CS was measured in one trial from the
beginning of CS until two hours postpartum inclusive of amni-
otic fluid (Abdel-Aleem 2013); in another trial from incision until
opening of the amniotic sac and then from placental separation
until the end of surgery (Senturk 2013); in one trial from the pla-
cental delivery till the end of surgery and till six hours postpartum
(Yehia 2014), one trial reported intraoperative blood loss inclusive
of amniotic fluid and blood loss from the end CS until two hours
postpartum (Movafegh 2011); in two trials from placental deliv-
ery until the end of surgery and from the end of surgery until two
hours postpartum (Goswami 2013; Shahid 2013) and in finally
in two trials from placental delivery until two hours postpartum
(Gai 2004; Xu 2013).
Excluded studies
We excluded five trials for the following reasons:
• two trials were published in abstract form only (Gobbur
2011; Tarabrin 2012) and one study as a preliminary report
(Halder 2013) and these publications do not contain sufficient
information for appraisal;
• two trials were quasi-randomised with randomisation done
by the rule of odds and even (Gohel 2007; Sekhavat 2009).
Risk of bias in included studies
The risk of bias of included trials are presented in Figure 2 and
Figure 3. The details of bias assessment are described in character-
istics of included studies tables.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Seven trials had low risk (Gai 2004;Gungorduk 2011;Gungorduk
2013; Mirghafourvand 2013; Movafegh 2011; Xu 2013; Yehia
2014); four trials had high risk (Abdel-Aleem 2013; Goswami
2013; Senturk 2013 Shahid 2013) and one trial had unclear risk
of random sequence generation bias (Yang 2001).
Five trials had low risk of bias allocation concealment (Gungorduk
2011; Gungorduk 2013; Mirghafourvand 2013; Xu 2013; Yehia
2014). Five trials had high risk of allocation bias (Abdel-Aleem
2013; Gai 2004; Goswami 2013; Senturk 2013; Shahid 2013)
and two trials unclear risk (Movafegh 2011; Yang 2001).
Blinding
Blinding was adequate in six trials (Goswami 2013;
Mirghafourvand 2013; Movafegh 2011; Shahid 2013; Xu 2013,
Yehia 2014). Three trials had high risk (Abdel-Aleem 2013; Gai
2004; Yang 2001) and three an unclear risk (Gungorduk 2011;
Gungorduk 2013; Senturk 2013) of performance and detection
bias.
Incomplete outcome data
All included trials had low risk of attrition bias except one (Yang
2001) with high risk.
Selective reporting
Only two trials had low risk of selective reporting bias (Gungorduk
2011; Gungorduk 2013). Two trials had a high risk of selective
reporting bias Goswami 2013; Shahid 2013, and eight trials had
an unclear risk of selective reporting bias (Abdel-Aleem 2013; Gai
2004; Mirghafourvand 2013; Movafegh 2011; Senturk 2013; Xu
2013; Yang 2001; Yehia 2014).
Other potential sources of bias
We have identified other potential sources of bias in four trials (
Abdel-Aleem2013;Gai 2004;Goswami 2013;Gungorduk 2011).
Effects of interventions
See: Summary of findings for the main comparisonTranexamic
acid versus placebo/no treatment for preventing postpartum
haemorrhage
All included trials used prophylactic uterotonic agents (as de-
scribed above) in addition to TA or placebo or nothing. TA was
used intravenously in all trials.
Comparison 1. TA versus placebo or no treatment
15Tranexamic acid for preventing postpartum haemorrhage (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Primary outcomes
1. Blood loss greater than 400 mL or 500 mL
Blood loss greater than 400 mL (Gai 2004; Yang 2001) or 500 mL
(Gungorduk 2013, Mirghafourvand 2013, Xu 2013, Yehia 2014)
was less common in women who received TA versus placebo or no
intervention (risk ratio (RR) 0.52, 95% confidence interval (CI)
0.42 to 0.63), six trials, 1398 participants) Analysis 1.1. As blood
loss greater than 400 mL was reported in two included studies
(Gai 2004; Yang 2001), we have taken it as a proxy for the primary
outcome. The data for two different doses on TA were combined
in the analysis.
The effect of TA on the blood loss greater than 400 mL or 500
mL was more pronounced in the group of women having vaginal
birth (RR 0.42, 95% CI 0.28 to 0.63, three trials, 832 women)
in comparison to women who had CS (RR 0.55, 95% CI 0.44 to
0.69, three trials, 566 participants) Analysis 1.1. see Summary of
findings for the main comparison
2. Blood loss greater than 1000 mL
Blood loss greater than 1000 mL was less common in women
who received TA in comparison to these who had placebo or no
intervention (RR 0.40, 95% CI 0.23 to 0.71, six trials, 2093
participants) Analysis 1.2.
TA in vaginal birth and in CS
TA was effective in decreasing the incidence of the blood loss
greater than1000mL inwomenwhohad undergoneCS (RR0.43,
95% CI 0.23 to 0.78, four trials, 1534 participants). In women
who had vaginal birth, the two trials with 559 participants had
very few outcomes (two versus seven; RR 0.28, 95% CI 0.06 to
1.36) Analysis 1.2.
Secondary outcomes
3. Mean blood loss
Mean blood loss was found to be lower in women who received
TA versus placebo or no intervention (mean difference (MD) -
77.79 mL, 95% CI -97.95 to -57.64, five trials, 1186 women),
with positive effect of TA on blood loss following both vaginal
birth (MD -80.56 mL, 95% CI - 104.80 to -56.33, three studies,
832 women) and CS (MD - 71.57 mL, 95% CI - 107.89 to -
35.26, two studies, 354 women) Analysis 1.3.
4. Use of additional medical interventions to control PPH
Additional medical interventions such as 200 mcg intravenous
methylergometrine, 20 IU oxytocin infusion in 500 mL of
Ringer’s lactate and/or 800 mcg misoprostol rectally (Gungorduk
2013; Mirghafourvand 2013), intramuscular methylergometrine
(Goswami 2013), additional uterotonic (unspecified) (Abdel-
Aleem 2013; Gungorduk 2013) were used less frequently in a
group of women receiving TA versus placebo or no interventions
(RR 0.48, 95% CI 0.34 to 0.68), five trials, 2049 participants)
Analysis 1.4.
5. Use of additional surgical intervention to control PPH
No additional surgical interventions were used in 2051 women
in four trials (Abdel-Aleem 2013; Gungorduk 2011; Gungorduk
2013; Yehia 2014) Analysis 1.5.
6. Blood transfusion
Less blood transfusions were administered to women who received
TA versus placebo or no intervention (RR 0.24, 95% CI 0.11
to 0.53, six trials, 1698 participants) Analysis 1.6, though this
differencewas only significant inwomenundergoingCS (RR0.23,
95% CI 0.10 to 0.54) and not vaginal birth (RR 0.33, 95% CI
0.03 to 3.17).
7. Maternal death and severe maternal morbidity
Four trials (1511 women) reported that there were no cases of
maternal death or severe maternal morbidity such as seizure,
thromboembolic events, need for intensive case unit admission,
hysterectomy, organ failure (Goswami 2013; Gungorduk 2011;
Mirghafourvand 2013, Yehia 2014) Analysis 1.7.
8. Side effects
More women who received TA versus placebo or no intervention
experienced side effects ((average RR 2.48, 95% CI 1.36 to 4.50,
eight trials, 2616 participants) Analysis 1.8. Considerable hetero-
geneity was detected in this analysis (I² = 83%; Tau² = 0.28).
Analysis of side effects in women who received TA versus follow-
ing vaginal birth showed that more women in the TA group in
comparison to placebo or no intervention developed side effects
(average RR 1.96, 95% CI 1.50 to 2.55, three trials, 740 women).
There was no heterogeneity in this analysis (I² = 0%). On the
other hand, a group of women who received TA before CS had a
tendency to a higher frequency of side effects, which was signif-
icant (average RR 3.78, 95% CI 0.69 to 20.66, five trials, 1876
participants) with a considerable heterogeneity I² = 90%, Tau² =
2.40.
One study reported on the following side effects: nausea, vomiting,
headache, skin reaction (Abdel-Aleem 2013), one study reported
16Tranexamic acid for preventing postpartum haemorrhage (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
only nausea (Goswami 2013), one study reported on nausea, vom-
iting and diarrhoea (Gungorduk 2011), one study reported nau-
sea, vomiting, diarrhoea, pyrexia, tachycardia, headaches, giddi-
ness, shivering (Gungorduk 2013), one study reported on dizzi-
ness and nausea (Mirghafourvand 2013), one study reported nau-
sea/vomiting, phosphenes, dizziness (Xu 2013), and one study re-
ported nausea, vomiting, dizziness (Yang 2001).
9. Thromboembolic events
There was no difference in the number of thromboembolic events
inwomenwho receivedTA versus placebo or no interventions (RR
0.98, 95% CI 0.14 to 6.78, 11 trials, 3012 participants) Analysis
1.9. Two episodes of deep venous thrombosis were reported in the
TA and placebo group in one study (Xu 2013).
Comparison 2. TA versus uterotonic
We did not find any studies comparing TA with uterotonic agents.
Comparison 3. Different doses of TA
Primary outcomes
1. Blood loss > 400 mL or > 500 mL
Only one study contributed data on the effect of different doses
(0.5 g versus 1 g IV) of TA on blood loss greater than 400 mL
(Yang 2001). There were no statistically significant differences in
blood loss greater than 400 mL (RR 0.49, 95% CI 0.19 to 1.25,
one study, 186 participants) Analysis 2.1.
2. Blood loss > 1000 mL
Two trials (Goswami 2013; Yang 2001) that assessed different
doses of TA did not study blood loss greater than 1000 mL.
Secondary outcomes
3. Mean blood loss
Two studies contributed data on the effect of different doses of TA
(0.5 g or 10 mg/kg versus 1 g or 15 mg/kg) on mean blood loss
and showed no difference between the groups (MD-58.86 mL,
95% CI -54.82 to 172.54), two studies, 246 participants) with
considerable heterogeneity (I² = 96%; Tau² = 6445.54) Analysis
2.2. Exploring heterogeneity, we found that one study (Yang 2001)
investigating the effects of TA in women who had a vaginal birth
had found no difference between the different doses on TA (MD
-0.40 mL, 95% CI -41.06 to 40.26), one study, 186 participants).
We cannot explain why the mean blood loss was slightly higher
in a group of women who received 1 g of TA versus group that
received 0.5 g TA. On the other hand, a study (Goswami 2013)
investigating the effects of different doses of TA in women who
had CS had found that women who received 15 mg/kg of TA had
less blood loss than women who received 0.5 g TA (MD 115.63
mL, 95% CI 92.31 to 138.95, one trial, 60 participants).
4. Use of additional medical interventions to control PPH
The same study (Goswami 2013) reported no difference in the
use of additional medical interventions to control PPH (RR 1.50,
95% CI 0.27 to 8.34) Analysis 2.3)
5. Use of additional surgical interventions to control PPH
No data available
6. Blood transfusion (not prespecified)
No data available
7. Maternal death or severe maternal morbidity such as
seizure, thromboembolic events, need for intensive care unit
admission, hysterectomy, organ failure
No data available
8. Mild side effects such as nausea, vomiting, headache, skin
reactions
No difference was found in mild side effects in women who re-
ceived different doses of TA (RR 2.00, 95% CI 0.19 to 20.90),
one trial, 60 participants Analysis 2.4).
9. Thromboembolic events
No thromboembolic events were reported in the same study (
Goswami 2013) Analysis 2.5.
Comparison 4. Different routes of administration of
TA
TA was used intravenously in all trials, therefore, this comparison
was not possible to perform.
Subgroup analysis
We planned to perform two subgroup analysis, i.e. women under-
going vaginal birth and CS; women who received and did not re-
ceive routine uterotonics. The data on the former subgroup analy-
sis are presented within Comparison 1 above. The latter subgroup
analysis was not possible as all participants in the included studies
received prophylactic uterotonic agents.
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Sensitivity analysis
For the purpose of sensitivity analysis, we excluded the trials that
did not use placebo (Abdel-Aleem 2013; Gai 2004; Yang 2001;
Yehia 2014) from the assessment of primary outcomes. Blood loss
> 400 mL or 500 mL was still less common in women undergoing
vaginal birth who received TA versus placebo (RR 0.43, 95% CI
0.23 to 0.80, two trials, 559 women). Althoughmore women who
had undergone CS had blood loss > 500 mL or > 400 mL, this
difference was no longer statistically significant when only trials
with placebo were analysed (RR 0.66, 95% CI 0.40 to 1.09, one
trial, 174 women). Overall, excluding trials without placebo did
not change the outcome of blood loss > 400 mL or 500 mL (RR
0.54, 95% CI 0.37 to 0.80, three trials, 733 women).
Similar trend was observed in the outcome of blood loss >1000
mL: there was no difference in the results in women who had
vaginal birth as all studies used placebo, more women had PPH
>1000 mL in the TA group versus placebo, but this result was
no longer statistically significant (RR 0.28, 95% CI 0.06 to 1.36,
three trials, 794 women), no difference in overall result for both
CS and vaginal birth studies (RR 0.37, 95%CI 0.21 to 0.67, five
trials, 1353 women).
D I S C U S S I O N
Summary of main results
Tranexamic acid (TA) is used widely to prevent haemorrhage. Our
review assessed 12 trials that fulfilled our inclusion criteria. The
summary of the main results is presented in Summary of findings
for the main comparison.
Our analysis showed that TA decreases blood loss greater than 400
mL or greater than 500 mL and this effect is more prominent in
the vaginal birth comparison than in the CS comparison based on
studies withmethodological shortcomings. Blood loss greater than
1000 mL decreased with the use of TA, however, the difference
was significant only in the caesarean section comparison and not
in the vaginal birth comparison in which there were few outcomes.
The use of additional medical interventions to control PPH was
higher in the placebo or no intervention groups versus the TA
group with more prominent differences in the vaginal birth group
in comparison to the CS group. No additional surgical procedures
to control PPH were used in three trials that reported on this
outcome. The sample size in this analysis is too small to evaluate
this outcome and further trials are necessary.
All women in all studies received routine uterotonics. No com-
parison between TA and uterotonics was investigated, nor was the
effect of TA in the absence of uterotonics, which may potentially
be greater.
Maternal death or severe maternal morbidity such as seizure, need
for intensive care unit admission, hysterectomy or organ failure did
not occur according to the two trials that reported this outcome. A
larger number of participants is required to evaluate this important
outcome.
Based on pooled data from all included trials except one study
(Yang 2001), we found no difference in thromboembolic episodes
between the two groups (11 trials, 3012 participants). One trial
(Xu 2013) evaluating TA in women undergoing CS reported two
episodes of deep venous thrombosis in two participants out of
88 in the TA group and in two participants out of 86 in the
control group. This is an unusual finding as the rate of this venous
thromboembolism following CS reported in the literature is less
than one per 1000 (James 2009). The participants in the Xu 2013
trial were low-risk women with routine postoperative care. It is
not clear why deep venous thrombosis was more common in this
study population. None of the participants in the other eight trials
experienced this complication.
More women who received TA versus placebo or no intervention
experienced side effects. This outcome had considerable hetero-
geneity (I² = 83%). There was no heterogeneity in this outcome
in the subgroup of women who had vaginal birth.
Women who have had a CS are expected to have more mild com-
mon side effects such as nausea, vomiting and dizziness, which can
be related to surgery and/or TA. Therefore, it is difficult to explain
the heterogeneity of these results and the studies did not report
on the same mild side effects. The studies that have introduced
heterogeneity to this analysis reported on the following side effects
- nausea, vomiting, headache and skin reaction in Abdel-Aleem
2013; only nausea in Goswami 2013, Gungorduk 2011 reported
on nausea, vomiting and diarrhoeaXu 2013 reported nausea/vom-
iting, phosphenes, dizziness.
Only two trials with unclear risk of bias and limited sample size
(Goswami 2013; Yang 2001) evaluated different doses of TA and
they only reported on a few outcomes. One trial compared 10
mg/kg and 15 mg/kg of TA (Goswami 2013). This trial included
women with average weight of 57 kg, therefore, women received
TA in the average dose of 0.6 g in one group and 0.9 g in the other
group. The other trial (Yang 2001) compared 0.5 g and 1 g TA
given following vaginal birth.We pooled data from both trials and
combined groups 10 mL/kg with 0.5 g TA and 15 mL/kg with 1
g TA. No difference was found in blood loss greater than 400 mL
and mean blood loss following vaginal birth between 0.5 g and 1 g
based on this single trial. Although mean blood loss following CS
was lower in women who received 15 mg/kg versus 10 mg/kg TA,
no difference was seen in the use of additional medical interven-
tions to control PPH in the same study population. The number of
side effects did not differ between the groups who received 10 mg/
kg versus 15 mg/kg TA based on a small number of participants.
No clear conclusions can be drawn from comparison of different
doses of TA for preventing PPH. One study (Yang 2001), which
was of limited quality, found marginally higher blood loss with
the higher dose of TA versus the lower dose.
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Overall completeness and applicability of
evidence
The studies included in themeta-analysis were undertaken in low-
and middle-resource settings, therefore, the results have wide ap-
plicability. The study population included only low-risk women,
but there is no biological reason to expect that TA would not have
similar effects in women at high risk of PPH, such as women with
placenta praevia, placental abruption, multiple pregnancy, instru-
mental delivery, prolonged labour as well as in women for whom
blood loss needs to be minimised, such as women with anaemia
or those who are haemodynamically unstable.
Although we did not find any data on cost-effectiveness of TA for
preventing PPH, it is worth noting that the cost of TA is low and
in bleeding trauma patients it was found to provide significant
savings in low-, middle- and high-income countries (Guerriero
2011). The cost of one vile of tranexamic acid (1 g) was reported
to be GBP 3.75 Sepah 2011. It can be stored at room temperature
(25°C). It is easily administered by intravenous injection.
Quality of the evidence
Included studies were mixed in terms of risk of bias. Five trials
had a low risk of selection bias, one trial had an unknown risk
of selection bias and six had either an unknown or a high risk of
selection bias. The risk of performance bias was low in six trials
and unknown or high in six trials. The risk of attrition bias was low
in all included trials except one. The risk of selective reporting was
generally unclear. Only two trials had registered the trial protocol.
All included trials except one used the standard method of mea-
suring blood loss. Gungorduk 2011 used preoperative and post-
operative haematocrit difference to calculate the blood loss and we
did not use the data on mean blood loss from this trial.
Five trials reported on blood loss from birth until two hours post-
partum (Gai 2004; Gungorduk 2013; Mirghafourvand 2013; Xu
2013; Yang 2001).We included the data on mean blood loss from
these trials in our analysis. Other trials included in this review
had estimated blood loss at different times points, e.g. one trial
included the blood loss from the beginning of CS until two hours
postpartum inclusive of amniotic fluid (Abdel-Aleem 2013); one
trial reported blood loss from incision until opening of the amni-
otic sac and then fromplacental separation until the end of surgery
(Senturk 2013); one trial reported intraoperative blood loss in-
clusive of amniotic fluid and blood loss from the end of CS until
two hours postpartum (Movafegh 2011), two trials reported on
blood loss from placental delivery until the end of surgery and
from the end of surgery until two hours postpartum (Goswami
2013; Shahid 2013). The data from these trials were not included
in this analysis.
High heterogeneity was observed in side effects outcome (I² =
83%) contributed by studies on the use of TA inCS (I² = 90%) and
not vaginal birth (I² = 0%). The heterogeneity is likely to be due to
different definitions of side effects in various trials. Interestingly,
two trials reported no side effects in placebo (Gungorduk 2011)
or no intervention (Yehia 2014) groups in women undergoing
CS. Such findings are unusual as the rate of nausea and vomiting
following CS is reported to be up to 35% (Noroozinia 2013).
Nausea and vomiting were included as part of side effects in both
trials.
Sensitivity analysis (excluding the trials that did not use placebo)
did not add any further information to our results.
The quality of evidence was assessed using the GRADE approach
for each of seven outcomes. The evidence was downgraded to
moderate quality due to concerns regarding study design for blood
loss 500 mL or more; blood loss 1000 mL or more; mean blood
loss volume (mL); and use of additional medical interventions to
control PPH. The evidence was downgraded to low quality for
maternal death or severematernal morbidity and thromboembolic
events due to study design limitations and imprecision (sample size
too small to detect this rare outcome). The evidence was down-
graded to moderate quality for mild side effects due to inconsis-
tency in the evidence (high heterogeneity I² = 83%).
Potential biases in the review process
We pooled results for PPH with blood loss greater than 400 mL
with the prespecified outcome blood loss greater than 500 mL
together. Only blood loss greater than 400 mL, which differed to
the primary outcome selected for this review (greater then 500
mL) was reported in two trials (Gai 2004; Yang 2001).The reasons
behind a choice of an outcome such as blood loss greater than 400
mL are not clear from these papers. The possibility exists that this
end-point may have been chosen retrospectively.
We have updated the outcomes being assessed in this review, e.g.
we added blood transfusion to secondary outcomes instead of hae-
moglobin below 6 g%. The reasons behind this change is the im-
portance of blood transfusion as an outcome when evaluating an
intervention for preventing haemorrhage. Blood transfusions are
used in the treatment of severe haemorrhage, they are costly, asso-
ciated with significant adverse reactions and may not be available
in low-resource settings. Blood transfusion is an outcome assessed
in other Cochrane reviews on PPH (Mousa 2014) and TA (Ker
2013; Perel 2013).
Mean blood loss following vaginal birth was measured at different
time points (from birth till placental delivery, fromplacental deliv-
ery till two hours postpartum and from birth till two hours post-
partum). Although initially our prespecified outcome was mean
blood loss from placental delivery until two hours postpartum,
we changed it to the mean blood loss from birth until two hours
postpartum to be able to pool data from all three trials on TA for
preventing PPH in vaginal birth.
All the above-mentioned measures increased the numbers in the
meta-analysis. The heterogeneity remained low.
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One study (Yang 2001) used aminomethylbenzoic acid in one
group, which was considered a placebo by the trial authors, though
there was also a group that did not received any intervention. We
included only the latter group.
Agreements and disagreements with other
studies or reviews
A recent meta-analysis of observational trials and randomised con-
trolled trials (RCTs) on usage of TA for obstetric haemorrhage
found that TA reduces the amount of blood loss following CS and
vaginal birth, and reduces the requirement for blood transfusion
(Peitsidis 2011), which is in agreement with our results. Peitsidis
and co-authors published a meta-analysis, which included stud-
ies with considerable heterogeneity (Peitsidis 2011). Abdel-Aleem
and co-authors presented a meta-analysis on TA effects on blood
loss following CS and also found positive effects of TA with con-
siderable heterogeneity (Abdel-Aleem 2013). Our results did not
have heterogeneity because we included only RCTs that evaluated
the prespecified outcomes in a similar manner.
One trial included in theCochrane review on treatment of primary
PPH (Mousa 2014) showed a trend to decrease the incidence of
severe PPH (greater than 800 mL) in a group of women who
receivedTA versus placebo (Ducloy-Bouthors 2011). TA decreases
the probability of blood transfusion following emergency surgery
(Perel 2013).
The effect of TA on mortality following emergency surgery was
reported to be uncertain in a recent Cochrane review that included
three trials (260 participants) (Perel 2013). A large high-quality
RCT showed a decrease in all-causes mortality and death due to
bleeding in trauma patients who received a short course of TA
versus placebo (CRASH-2 trial collaborators). Mousa and co-au-
thors did not show any benefits of TA for treatment of primary
PPH in relation to maternal mortality, admission to intensive care
unit and hysterectomy following vaginal birth based on the same
trial (Ducloy-Bouthors 2011; Mousa 2014). This trial was under-
powered to evaluate these rare outcomes. Findings of our review
are consistent with previous reports on the need for further well-
designed studies with a larger number of participants to evaluate
the effect of TA on maternal mortality, severe morbidity and ad-
ditional surgical interventions to control PPH.
Prophylactic oxytocin in comparison to placebo is effective in pre-
venting PPH greater than 500 mL according to a recent Cochrane
review (RR 0.53, 95% CI 0.38 to 0.74, 6 trials 4203 women)
(Tunçalp 2012) and the relative risk is comparable to the effects
of TA on PPH greater than 400 or 500 mL in our meta-analysis
(0.53, 95% CI 0.41, 0.69, five trials, 1188 women). Prophylactic
ergometrine-oxytocin is associated with a small reduction of PPH
greater than 500 mL (OR 0.82, 95% CI 0.71 to 0.95) according
to another Cochrane review (McDonald 2004). Interestingly, the
effect of TA in addition to prophylactic oxytocin in our meta-
analysis is more prominent than the effect of ergometrine.
A recent well-designed trial on the use of TA following vagi-
nal birth for treatment of PPH (144 participants) reported three
cases of deep vein thrombosis at the site of intravenous catheter
(two in the tranexamic acid group and one in the control group)
(Ducloy-Bouthors 2011). Although the association of TA with
thromboembolic events has been hypothesised, but has not been
proven to date (CRASH-2 trial collaborators; Gandhi 2013; Ker
2012; Ker 2013; Poeran 2014), this review is in agreement with
other publications suggesting that larger studies are required to
assess this outcome and establish the safety of TA.
Mild side effects are more common in TA versus placebo or no
intervention (Ducloy-Bouthors 2011; Peitsidis 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence presented in this review suggests that TA is an ef-
fective drug for preventing PPH based on data from trials in low-
risk women. The increase in mild side effects with the use of TA
versus placebo or no intervention should be considered.
Implications for research
Further research is needed to examine the effects ofTAonmaternal
mortality, severe morbidity and thromboembolic events. Studies
assessingTA for preventingPPH inhigh-riskwomenwith placenta
praevia, placental abruptio, uterine rupture and other conditions
causing PPH are important. Comparison of different doses of TA
as well as prophylactic use of TA without prophylactic uterotonics
is necessary, using large, well-designed trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abdel-Aleem 2013
Methods Randomised controlled trial undertaken in Egypt.
Participants 740 pregnant women with singleton fetus at > 37 weeks’ gestation undergoing elective
CS were considered potentially eligible for the study. Women were considered ineligible
if they had any of the following: history of medical disorders, pre-eclampsia, antepar-
tum haemorrhage, history of thromboembolic disorders, polyhydramnios, macrosomia,
history of sensitivity to TA and taking anticoagulant therapy
Interventions Intervention group (N = 373) received TA 1 g in 20 mL of 5% glucose, given slowly IV
over 10 minutes before the operation commenced
The control group (N = 367) received routine care.
All received oxytocin (5 IU IV bolus and 20 IU IV infusion) according to hospital policy
or judgement of the surgeon
Outcomes Primary outcome - mean blood loss (mL) (during operation and for 2 hours after oper-
ation)
Secondary outcomes - incidence of PPH, cases with postpartum blood loss > 500 mL
and > 1000 mL, use of additional uterotonics, use of additional surgical intervention to
control PPH, the incidence of mild side effects such as (nausea, vomiting, headache, skin
reaction), mean change in haematocrit value, mean change in the haemoglobin value,
number of hospital admission days, serious adverse events as thromboembolic event,
admission to ICU and state of the patient at discharge
Notes More women in intervention group had BMI > 30, were anaemic and had longer time
of surgery. More women in control group had manual removal of placenta and more
women in intervention group had placenta removed by controlled cord traction
Blood lossmeasurement - blood loss included blood loss duringCS and 2 hours following
operation determined using calibrated drapes. Amniotic fluid was also included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Computer-generated random numbers,
however, groups were unequal - women in
intervention group had BMI > 30, were
anaemic andhad longer time of surgery and
more women in control group had manual
removal of placenta and more women in
intervention group had placenta removed
by controlled cord traction
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Abdel-Aleem 2013 (Continued)
Allocation concealment (selection bias) High risk Women were enrolled in the operating
room before induction of anaesthesia by
opening the opaque sealed envelopes that
were consecutively numbered. See above
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The injection was given by the anaes-
thetist as requested by the researcher with-
out knowing the nature of the trial
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The control group did not receive any in-
tervention, there was no placebo used
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The researcher was aware of allocation to
the groups.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data on all outcomes complete.
Selective reporting (reporting bias) Unclear risk Noprotocol was registered prior to the trial.
Other bias High risk 1. Imbalances despite randomisation: De-
spite high-quality randomisation and allo-
cation concealment more women in inter-
vention group hadBMI > 30, were anaemic
and had longer time of surgery and more
women in control group had manual re-
moval of placenta and more women in in-
tervention group had placenta removed by
controlled cord traction
Gai 2004
Methods Randomised controlled trial undertaken in 3 centres in China
Participants 180 primiparas healthy women at term with singleton who underwent CS
Interventions Intervention group (N = 91) - 1 g (10 mL) of TA diluted in 20 mL 5% glucose given
IV slow infusion over 5 minutes 10 minutes before incision
Control (N = 89) - received routine care.
Outcomes Blood loss fromplacental delivery until 2 hours postpartum, incidence of PPH(blood loss
> 400mL), vital signs, uterine contractility, placental separation, neonatalmanifestations,
side effects
Notes No placebo was used. Women in both control and study groups received 10 units of
oxytocin IV and 20 units of oxytocin into the intrauterine wall
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Gai 2004 (Continued)
The same surgical team performed CS in each hospital.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised consecutive numbered chart.
Allocation concealment (selection bias) High risk Control group did not receive any inter-
vention, therefore, allocation was not con-
cealed
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No intervention was administered to con-
trol group, therefore, blinding was not pos-
sible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk The data seem complete.
Selective reporting (reporting bias) Unclear risk No prior public registration of protocol.
Other bias High risk PPH>400mL and not conventional > 500
mL. No placebo used.
No sample size calculation.
Goswami 2013
Methods Randomised controlled trial undertaken in India.
Participants 90 women ASA grade I and II patients, age more than 18 years and anaemic patients
with haemoglobin 7-10 g%, undergoing CS.
Exclusion criteria: ASA physical status III and IV; history of coagulopathy or throm-
boembolism, or both; patients who had received Acenocoumerol or platelet antiaggre-
gant such as aspirin in the week before surgery or non-steroidal anti inflammatory drugs
2 days before surgery; preoperative plasma creatinine greater than 130 µmol/L; myocar-
dial infarction or chronic arteriopathy or unstable angina in the previous 12 months;
mental status preventing them from understanding the study prospectus; renal or hepatic
impairment or any hypersensitivity to TA
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Goswami 2013 (Continued)
Interventions Control group (N = 30) - 5 mL of distilled water in 20 mL of 5% glucose
Group T1 (N = 30) - TA 10 mg/kg in 20 mL of 5% glucose.
Group T2 (N = 30) - TA 15 mg/kg in 20 mL of 5% glucose.
The drug in all the groups was given IV over 20 minutes before skin incision
Outcomes Blood loss was measured intraoperatively and postoperatively up to 24 hours, uterine
contractility, placental separation, neonatal condition and any side effects; methyler-
gometrine intramuscular - a rescue uterotonic treatment when required; postoperative
haemoglobin, haematocrit, serum creatinine, prothrombin time, and INR values were
recorded at 24 hours
Notes This trial included only anaemic women with haemoglobin of 7-10 g%
We used blood loss during surgery for mean blood loss outcome
We combined 2 intervention groups that received different doses of TA
Definition of PPH is not mentioned in the report. Reported that there was no incidence
of PPH in any of the patients
Blood loss - was measured during the surgery. Volume in suction bottle before placental
delivery was not included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “All participants were recruited as a consec-
utive series to one of the three study groups
of 30 patients each.”
Allocation concealment (selection bias) High risk Neither the patient nor the investigator was
aware of the group assignment. An anaes-
thetist not related to the study prepared the
drug for every patient. It is unclear how the
allocated interventionwas concealed, as the
IV infusion would be visible to all
Blinding (performance bias and detection
bias)
All outcomes
Low risk Neither the patient nor the investigator was
aware of the group assignment. An anaes-
thetist not related to the study prepared the
drug for every patient
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither the investigator nor the patient was
aware of group assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data are complete.
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Goswami 2013 (Continued)
Selective reporting (reporting bias) High risk No pre-trial public registration of protocol.
Although the authors stated that the blood
loss was measured during surgery and ev-
ery 2 hours for 6 hours postoperatively and
then 6 hourly for 24 hours the data were
presented only on intraoperative blood loss.
The authors stated that postoperative blood
loss was minimal
Other bias High risk Definition of PPH not mentioned in the
report.Women enrolledwere anaemicwith
haemoglobin 7-10 g%
It is unclear how the sample size was calcu-
lated.
The groups were not equal - the duration
of CS was longest in group 2
We combined groups that were adminis-
tered different dosages of TA using above-
described methods
Gungorduk 2011
Methods Randomised controlled trial undertaken in Turkey.
Participants Women more than 38 gestational weeks requiring elective CS without risk factors for
PPH (anaemia with haemoglobin < 7 g%, multiple gestation, antepartum haemorrhage
(placenta praevia or placental abruption), abnormal placentation, uterine fibroids, poly-
hydramniosis, emergency CS, history of uterine atony or PPH, history of significant
disease
Interventions Intervention group (N = 330) - 1 g/10 mL TA diluted in 5% 20 mL glucose given IV
over 5 minutes 10 minutes prior to skin incision
Control group (N = 330) - 30 mL 5% dextrose given in the same manner as above
Both groups received 5 IU of IV oxytocin as a bolus following delivery of the baby
followed by 30 IU of oxytocin in 500 mL lactate Ringer’s solution infused at 125 mL/hr
Outcomes Primary outcome - estimated blood loss (calculated based on a formula using preoperative
and postoperative haematocrit at 48 hours and women’s weight)
Secondary outcomes - PPH, use of additional uterotonics, need for blood transfusion,
TA side effects, duration of mother’s hospital stay, neonatal outcome
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Gungorduk 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Low risk Randomisation was performed by a phar-
macist who prepared infusion bags
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Infusion bags with TA and placebo were
prepared by a pharmacist and marked A
or B. Neither study staff nor participants
were aware of the content of the infusion
bags, however, having bags marked differ-
ently might introduced bias
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Neither study staff nor participants were
aware of the content of the infusion bags
with the studymedication or placebo, how-
ever, having bags marked differently might
introduced bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data reported.
Selective reporting (reporting bias) Low risk The trial protocol was registered at http://
www.controlled-trials.
com - ISRCTN42314355. All prespecified
outcomes were reported
Other bias High risk Blood loss calculation was done differently
to all other trials based on patients weight
and difference in haematocrit preopera-
tively and 48 hours after CS. This method
of estimating blood loss differs from clini-
cal practice
Gungorduk 2013
Methods Randomised controlled trial undertaken in Turkey.
Participants Gestational age 34 to 42 weeks, a live fetus, cephalic presentation, expected vaginal birth
Exclusion criteria: multiple gestation, polyhydramnios, estimated fetal weight > 4500 g,
grand multiparity (5 or more), pre-eclampsia, or previous PPH, placenta praevia, pla-
cental abruption, CS, or any uterine scarring, abnormal placentation (accreta, increta,
percreta), history of thromboembolic disease, and a current or previous history of sig-
nificant disease, including heart disease and liver and renal disorders
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Gungorduk 2013 (Continued)
Interventions Intervention group (N = 220) - 1 g/10 mL TA diluted in 5% 20 mL glucose given IV
over 5 minutes at the time of delivery of the anterior shoulder of the baby
Control group (N = 219) - 30 mL 5% glucose given in the same manner as above
Routine management including uterotonics of third and 4th stages of labour in both
groups
Outcomes Primary outcome - the volume of blood loss from placental delivery until 2 hours post-
partum
Other outcomes - PPH (> 500 mL), severe PPH (> 1000 mL), need for blood trans-
fusion, need for additional uterotonic drugs (200 mcg IV methylergometrine, 20 IU
oxytocin infusion in 500 mL of Ringer’s lactate and/or 800 mcg misoprostol rectally)
, and side effects of TA injection (such as thrombotic events and gastrointestinal side
effects including nausea, vomiting, or diarrhoea)
Notes Blood loss measured from the end of delivery until 2 hours postpartum
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Low risk Randomisation was performed by a phar-
macist who prepared infusion bags
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Infusion bags with TA and placebo were
prepared by a pharmacist and marked A
or B. Neither study staff nor participants
were aware of the content of the infusion
bags, however, having bags marked differ-
ently might have introduced bias
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Neither study staff nor participants were
aware of the content of the infusion bags,
however, having bags marked differently
might have introduced bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk After randomisation 7 (3%) participants
excluded from control group (5 had CS, 1
chorioamnionitis, 1 delivery in bed) and 8
(3%) participants excluded from interven-
tion group (6 had CS, 2 delivery in bed)
though they have received the study inter-
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Gungorduk 2013 (Continued)
vention. It is not clear why participants de-
livered in bedwere excluded from the study.
There might have been difficulties measur-
ing blood loss in such cases
Selective reporting (reporting bias) Low risk Trial was registered at clinicaltrial.gov -
NCT01338454.
Other bias Low risk No other bias identified.
Mirghafourvand 2013
Methods Randomised controlled trial undertaken in Iran.
Participants 120 pregnant women 18-35 years with a singleton pregnancy, cephalic presentation and
normal blood pressure who had indication for vaginal delivery
Exclusion criteria were grand multiparity, long-term induction in first stage of labour
(oxytocin administration for at least 12 hours), previous history of caesarean delivery or
uterine surgery, uterine myoma, history of heart, liver, renal and brain diseases, history of
coagulation disorders and thromboembolic disease, blood disorders, history of diabetes
and pre-eclampsia, PPH and haemorrhage during current pregnancy, placenta praevia,
abnormal placenta, multiple pregnancies, macrosomia, polyhydramnios, instrumental
delivery or continuous pressure in the fundus of the uterus before the fetal expulsion
Interventions Intervention group (N = 60) - 1 g TA IV in 200 mL of normal saline over 10 minutes
after delivery of the anterior shoulder
Control group (N = 60) - 200 mL normal saline administered in the same manner as
above
Both groups got 10 units oxytocin after placenta delivery.
Outcomes Haemoglobin and haematocrit levels were measured 1-12 hours before and 12-24 hours
after delivery. Blood loss was measured from fetus delivery until placental delivery and
from placental delivery until 2 hours postpartum, blood loss > 500 mL, use of additional
uterotonics (20 IU oxytocin in 500 mL of Ringer’s lactate, 200 mcg methylergometrine
intramuscular and 800 mcg misoprostol rectally, side effects (nausea and dizziness)
Notes Publsihed in abstract form only in English. The full paper is currently in press in
ANZJOG. The data included in meta-analysis provided by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation, stratified according
to number of births (first and second and
more childbirths) with block sizes of 4 and
6 and allocation ratio of 1:1
32Tranexamic acid for preventing postpartum haemorrhage (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mirghafourvand 2013 (Continued)
Allocation concealment (selection bias) Low risk Opaque sequentially numbered sealed
packages.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Data assessor, participants and analysts had
no knowledge of type of intervention was
administered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Data assessor, participants and analysts had
no knowledge of type of intervention was
administered
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data assessor, participants and analysts had
no knowledge of type of intervention was
administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes reported.
Selective reporting (reporting bias) Unclear risk No protocol was registered.
Other bias Low risk No other bias identified.
Movafegh 2011
Methods Randomised controlled trial undertaken in Iran.
Participants 100 women aged 20-40 years with a singleton pregnancy at between 38 weeks + 5
days and 40 weeks’ gestation, who were categorised as class 1 ASA and were scheduled
to undergo CS by Pfannenstiel incision under spinal anaesthesia for malpresentation,
contracted pelvis, or patient request
Exclusion criteria were previous history of CS or intra-abdominal surgery; polyhydram-
niosis, macrosomia, pre-eclampsia or abnormal placenta; thrombophilia, anaemia, or
coagulopathy; cardiovascular, renal, or liver disorders; or contraindication to any drug
used in the study protocol
Interventions Intervention group (N = 50) - 10 mg/kg TA IV in 200 mL of normal saline infused over
10 minutes, 20 minutes before beginning spinal anaesthesia
Control group (N = 50) - 200 mL of normal saline.
Following delivery of the placenta both groups received 10 units of oxytocin in 500 mL
of normal saline IV over20 minutes
All patients then received 30 units of oxytocin during the first 8 hours postoperatively
A further 10 units of oxytocin was infused in the case of uterine atony
Outcomes Blood loss intraoperative and 2 hours after surgery (reported separately), the amount of
oxytocin administered in units, postoperative haemoglobin, platelets, PT, PTT and their
decline
33Tranexamic acid for preventing postpartum haemorrhage (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Movafegh 2011 (Continued)
Notes No side effects in TA group.
Blood loss was reported separately during CS and 2 hours after CS. Blood loss included
amniotic fluid volume. We have used intraoperative blood loss
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk All of the solutions were prepared by an
anaesthetist who was not involved in pa-
tient management or assessment; both the
patients and investigators were blinded to
the group assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both the patients and investigators were
blinded to the group assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The investigators were blinded to the group
assignment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete data.
Selective reporting (reporting bias) Unclear risk No prior registration of the protocol.
Other bias Low risk None identified.
Senturk 2013
Methods Randomised controlled trial undertaken in Turkey.
Participants Women undergoing elective or urgent CS.
Exclusion criteria - high BMI, venous thromboembolism, uterine myoma, active liver
or kidney diseases, polyhydramnios and overweight fetus, allergies to TA or other drugs,
especially NSAID, or patients receiving antithrombotic treatment
Interventions Intervention group (N = 122) - 1 g TA in 20 mL 5% glucose IV over 5 minutes 10
minutes before anaesthesia
Control group (N = 101) - 20mL 5% glucose solution administered in the samemanner
as in intervention group
All patients received 20 IU oxytocin IV in bolus form after removal of placenta
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Senturk 2013 (Continued)
Outcomes Blood loss (from incision until opening of the amniotic sac and then from placental
separation until the end of surgery)
Other outcomes - haemoglobin difference, haematocrit difference, red blood cell count
difference, pre- and postoperative haemoglobin
Notes All patients were operated under spinal anaesthesia by 2 surgeons
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Random number table.
Allocation concealment (selection bias) High risk Not described.Discrepancy in numbers
(122 vs 101).
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double-blind in title, but no description in
methods.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind in title, but no description in
methods.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind in title, but no description in
methods.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete data.
Selective reporting (reporting bias) Unclear risk No prior registration of protocol.
Other bias High risk No description of blinding.
Shahid 2013
Methods Randomised controlled trial undertaken in Pakistan.
Participants Women at term primipara/multiparas (parity not more than 2) with a singleton preg-
nancy being delivered by CS
Exclusion criteria - medical problems involving the heart, liver, kidney, brain, having
blood disorders, allergy to TA, history of thromboembolic disorders, abnormal placenta-
tion, severe pre-eclampsia, multiple pregnancy, macrosomia, polyhydramnios and those
requiring blood transfusion due to anaemia
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Shahid 2013 (Continued)
Interventions Intervention group (N = 38) - 1 g/10 mL TA in 20 mL of 5% glucose administered 10
minutes prior to skin incision
Control group (N = 36) - distilled water was diluted with 20 mL of 5% glucose admin-
istered in the same manner as above
Both groups - 5 IU IV bolus of oxytocin and 0.4 mg methylergometrine after delivery
of the neonate and 30 IU oxytocin in 500 mL of lactated Ringer’s solution IV infusion
at a rate of 125 mL/hour over 6 hours
Outcomes Heart rate, respiratory rate and blood pressure checked and noted before the surgery,
immediately after placental delivery and 1 and 2 hours after birth
The blood loss was measured following placental delivery to the end of the surgery, and
from the end of the operation to 2 hours after birth. Blood collected from the suction
container (the volume was measured in mL as marked on the container) was noted and
soaked mops, pads, and operation table sheet were weighed by electronic scale before
and after the surgery
Uterine contractility, placental separation, neonatal manifestations, and side effects were
noted
Haemoglobin, urine analysis, liver and renal function were noted before and on the 3rd
day after the operation
Notes Blood loss measured from placental delivery until the end of surgery and from the end
of surgery until 2 hours postpartum separately. PPH definition was not mentioned, but
reported decrease in PPH from 30% in placebo group to 13% in TA group. We were
unable to use any data on blood loss outcomes from this study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “The investigator has packed 50 pieces of
TA (1 G) and 50 pieces of distilled wa-
ter in identical opaque paper bags. Ran-
domisation was simple, by picking-up the
opaque paper bags containing either 1 G
TA, or equivalent numbers of distilled wa-
ter (placebo) ampoules at random.” It is not
clear how sequence generation was done
Allocation concealment (selection bias) High risk The study medications packed by investi-
gator were in opaque paper bags
Blinding (performance bias and detection
bias)
All outcomes
Low risk Anaesthetist administered study medica-
tion. Neither investigator nor patient were
aware ofwhatmedicationwas administered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither investigator nor patient were aware
of what medication was administered
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Shahid 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Neither investigator nor patient were aware
of what medication was administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data complete.
Selective reporting (reporting bias) High risk No prior registration of protocol.
Some data are not presented (e.g. side ef-
fects) and the report states that there was
no difference between the groups
Other bias Low risk
Xu 2013
Methods Randomised controlled trial undertaken in China.
Participants 176 primipara with a singleton pregnancy undergoing CS by Pfannenstiel incision under
spinal anaesthesia
Exclusion criteria: < 18 years, severe medical and surgical complications involving the
heart, liver or kidney, brain disease and blood disorders were present, allergy to TA,
multiple pregnancies,macrosomia or polyhydramnios, knownhaemostatic abnormalities
before pregnancy
Interventions Intervention group (N = 88) - 10 mg/kg TA in 200 mL of normal saline IV infused over
10 minutes, 20 minutes after beginning of anaesthesia
Control group (N = 86) - 200 mL of normal saline administered in the same manner as
above
Both groups - 10 units of oxytocin in a pint of dextrose normal saline IV over 30 minutes
and 0.4 mg of methylergometrine IV after delivery of the neonate
Outcomes Blood loss - from placental delivery to 2 hours postpartum, PPH > 500 mL. Severe side
effects - deep vein thrombosis, renal failure, seizures, maternal death; non-severe side
effects - nausea/vomiting, phosphenes, dizziness
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Low risk Opaque sealed envelopes.
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Xu 2013 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Anaesthetist not involved in the study pre-
pared the solutions
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Anaesthetist not involved in the study pre-
pared the solutions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Anaesthetist not involved in the study pre-
pared the solutions
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 patients out of 176 excluded due protocol
violation, therefore, the data presented for
174 patients
Selective reporting (reporting bias) Unclear risk No prior publication of protocol.
Other bias Low risk No other bias.
Yang 2001
Methods Randomised controlled trial undertaken in China.
Participants 400 primiparous women with term singleton pregnancy, vertex presentation, sponta-
neous delivery, normal antenatal care, no antepartum haemorrhage, no above moderate
PIH, no polyhydramnios, no abnormal birth process or other complications were en-
rolled in the 2nd stage of labour. Had 10 units of oxytocin injected immediately post
delivery
Interventions 4 groups: I) - TA 1 g IV (N = 94), 2) - TA 0.5 g IV (N = 92), 3) - aminomethylbenzoic
acid 0.5 g IV (N = 92), 4) - no treatment (N = 87)
TA was given IV 2 to 3 minutes after the delivery.
Outcomes Incidence of PPH, mean blood loss (from placental delivery until 2 hours postpartum),
side effects
Notes Aminomethylbenzoic acid is an antifibrinolytic. There was no placebo used in group 4.
Not blinded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned to 4 groups.
Allocation concealment (selection bias) Unclear risk Not described.
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Yang 2001 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk Open labelled.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
High risk 35 cases of fetal macrosomia (> 4000 g)
were excluded from the study
Selective reporting (reporting bias) Unclear risk No prior publication/registration of proto-
col.
Other bias Unclear risk Wehave combined2 groupswhich received
2 different doses of TA using the above-
described methods. We did not include a
group that received aminomethylbenzoic
acid in this analysis
Yehia 2014
Methods Randomised controlled double-blinded trial.
Participants 223 women undergoing elective CS.
Exclusion criteria - medical disorders in pregnancy, bleeding tendency, risk of throm-
boembolism, known allergy to TA, antepartum haemorrhage, abnormal site of placenta,
macrosomic baby, twin pregnancy, polyhydramnios
Interventions Intervention group - TA 1 g with induction of anaesthesia by slow IV injection over 2
minutes in addition to 10 IU of oxytocin injection after delivery of the baby
Control group - 10 IU of oxytocin injection after delivery of the baby
Outcomes Primary - blood loss during CS after delivery of placenta.
Secondary outcomes - vital data during first 2 hours postpartum, vaginal bleeding during
6 hours postpartum, 24 hours postoperative haemoglobin and haematocrit values, need
for other surgical measures to stop bleeding (B-Lynch, uterine artery ligation, internal
iliac artery ligation, hysterectomy, transfusion of blood or blood products), maternal and
neonatal side effects of medications given
Notes
Risk of bias
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Yehia 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation coding tables were used.
Allocation concealment (selection bias) Low risk Sealed envelopes.
Blinding (performance bias and detection
bias)
All outcomes
Low risk See below.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Surgeons and investigators were not aware
whether patient received TA or not. No
placebo was used, therefore, participants
were aware of allocation group. However,
participants knowledge of the group allo-
cation is unlikely to have influenced the
blood loss or other objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation coding tables were con-
cealed from investigators till the end of the
trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 women in group 1 and five women in
group 2 were excluded from this study (ei-
ther due touterine contractions before elec-
tive CS or no available suction set in the
operative room)
Selective reporting (reporting bias) Unclear risk No prior registration/publication of the
study protocol.
Other bias Low risk None identified.
BMI: body mass index
CS: caesarean section
ICU: intensive care unit
INR: international normalised ratio
IU: international units
IV: intravenously
NSAID: non-steroidal anti-inflammatory drug
PIH: pregnancy-induced hypertension
PPH: postpartum haemorrhage
PT: prothrombin time
PTT: partial thromboplastin time
TA: tranexamic acid
40Tranexamic acid for preventing postpartum haemorrhage (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gobbur 2011 Randomised controlled trial, but sequence generation and allocation concealment were not described. Intervention
group (N = 50) - 1 g of TA IV 20minutes prior to CS. Control group (N = 50) - received no intervention. Outcomes
- blood loss from placental delivery until the end of CS and until 2 hours postpartum
This study was published only in abstract form in 2011. The information in the abstract is not sufficient for
adequate appraisal.
Gohel 2007 This was a quasi-randomised trial (randomisation by the rule of odds and even).
This study reported decreased blood loss in 50 women who received 1 g of TA IV 20 minutes prior to CS, in
comparison to 50 women who did not receive the drug. No side effects were reported in either group
Halder 2013 Although the title of this report says “randomised case-controlled study” it is not clear from the report whether the
study was indeed randomised. It states that participants were divided in 2 groups, but there is not any description
of sequence generation or allocation concealment.
The blood loss is measured from placental delivery to 2 days postpartum and no difference between the groups was
found
Sekhavat 2009 This was a quasi-randomised trial (randomisation by the rule of odds and even).
This study reported decreased blood loss from the end of CS until 2 hours postpartum in 45 women who received
1 g of TA IV 10 minutes prior to CS, in comparison to 45 women who did not receive the drug. Haemoglobin
level was significantly greater in TA group. No side effects were reported in either group
Tarabrin 2012 This trial in published only in 2 abstracts. Information provided in abstracts is not sufficient for adequate
appraisal.
CS: caesarean section
IV: intravenously
PPH: postpartum haemorrhage
TA: tranexamic acid
Characteristics of studies awaiting assessment [ordered by study ID]
Ahmed 2014
Methods Prospective randomised trial, patients equally divided into 2 groups
Participants 124 women undergoing CS.
Interventions Intervention group - 10 mg/kg TA 5 minutes before skin incision
Both groups received 10 unit of oxytocin and 1 mL of ergometrine after delivery of the baby
Outcomes Blood loss from placental delivery till the end of surgery and from the end of surgery until 2 hours postpartum,
haemoglobin and haematocrit levels on day 3 postpartum, maternal and neonatal adverse effects
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Ahmed 2014 (Continued)
Notes Blood loss 391 mL in intervention groups versus 597 mL in control group. Published in abstract form only. Unable
to contact the authors to get more information. The abstract does not contain sufficient information on study
design (randomisation, allocation concealment) for appraisal. Awaiting full publication of the study at this stage.
Bhavana 2013
Methods Randomised controlled trial.
Participants 200 term pregnant women.
Interventions Intervention group (N = 100) received IV 1 g TA in 20 mL 5% dextrose and before CS
Control group (N = 100) received 20 mL normal saline.
All participants received 10 U oxytocin IM after delivery of neonate
Outcomes Blood loss occurred during and 6 hours after surgery; requirement of additional oxytocics; blood transfusion; side
effects and adverse effects
Notes The blood loss estimated during surgery was less in the TA group (511.3 +/-164.45 mL) than the control group
(637.9+/-429.77 mL) P < 0.0065. The blood loss in the postoperative period for 6 hours was less in the TA group
(P < 0.0015).The need for additional oxytocics and blood transfusion was less in the TA group. Similarly the drop
of haemoglobin and haematocrit after surgery was less in the TA group. Side effects observed were mild nausea,
vomiting, diarrhoea. No difference in Apgar score and birthweight of neonates was observed in both of the groups
The abstract does not contain sufficient information on study design (randomisation, allocation concealment)
for appraisal.
CS: caesarean section
IM: intramuscularly
IV: intravenously
TA: tranexamic acid
Characteristics of ongoing studies [ordered by study ID]
Farber 2013
Trial name or title Tranexamic acid and thromboelastography during cesarean delivery
Methods Randomised, double-blind, controlled trial with 4 study arms. Assignment parallel
Participants Control - low risk for PPH (50 patients) and high risk for PPH (50 patients)
Intervention - low risk for PPH (50 patients) and high risk for PPH (50 patients)
Women ASA class I or II aged 18-50 years with singleton vertex pregnancy scheduled for elective CS (with
or without prior labour) with a planned Pfannensteil incision
Exclusion criteria: allergy to tranexamic acid; history of inherited or acquired thrombophilia; history of deep
vein thrombosis or pulmonary embolism, or use of anticoagulant medication; pre-eclampsia, haemolysis,
elevated liver enzymes, low platelet syndrome, seizure disorder
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Farber 2013 (Continued)
Interventions Intervention group - 1 g tranexamic acid in 100 mL normal saline given over 10 minutes
Control group - 100 mL 0.9% normal saline.
Outcomes Thromboelastography values will be compared in patients who receive prophylactic tranexamic acid or placebo
before surgery, during elective caesarean delivery, and 2 hours postpartum
Intraoperative blood loss - during surgery in the operating room. Blood loss will be measured using the
following methods: visual estimate of blood in the suction canister; weight of surgical sponges; postoperative
haemoglobin values
At 6 weeks postpartum - delayed bleeding complications, defined as obstetric bleeding requiring surgical
intervention, blood transfusion, or both; thrombotic complications including: venous thrombus seen on
ultrasound, thromboembolic event
Starting date JAN 2014.
Contact information Dr Michaela Kristina Faber, Brigham and Women’s Hospital, United States, mkfarber@partners.org
Notes
Sentilhes 2014
Trial name or title Tranexamic acid for preventing postpartum haemorrhage following a vaginal delivery (TRAAP)
Methods Randomised controlled double blind trial.
Participants Estimated 4000 women undergoing planned vaginal delivery, older than 18 years, with singleton pregnancy,
more than 35 weeks’ gestation
Interventions 1 g TA IV within 2 minutes of birth and prophylactic oxytocin administration versus placebo
Outcomes Primary - incidence of PPH (> 500 mL) , Secondary - mean blood loss at 15 minutes after birth, mean
total blood loss up to 24 hours after birth, incidence of severe PPH (> 1000 mL) 24 hours after birth,
need for supplementary uterotonic treatment, proportion of women requiring supplementary uterotonic
treatment including sulprostone, postpartum transfusion, proportion of women transfused in postpartum,
need for invasive second-line procedures for PPH (any of the following: arterial embolization, pelvic arterial
ligation, uterine compression suture, hysterectomy), haemoglobin peripartum delta (2 days postpartum),
mean difference between the haemoglobin values before delivery and on the 2nd day postpartum in the
absence of a transfusion of packed red blood cells, haematocrit peripartum delta (2 days postpartum), mean
difference between the haematocrit values before delivery and on the 2nd day postpartum in the absence
of a transfusion of packed red blood cells, haemodynamic tolerance (time frame: 15, 30, 45, 60 and 120
minutes after delivery - heart rate, blood pressure), mild adverse effects, stay in labour ward, nausea, vomiting,
phosphenes, dizziness, tolerance lab tests (urea, creatinaemia, prothrombin time, active prothrombin time,
fibrinogenaemia, aspartate and alanine transaminase, total bilirubin). Severe adverse effects (up to 12 weeks
after delivery - deep venous thrombosis, pulmonary embolism, myocardial infarction, renal failure needing
dialysis), other outcome measures: women’s satisfaction, psychological status
Starting date January 2015.
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Sentilhes 2014 (Continued)
Contact information Mathilde Moreau
Angers Univeristy Hospital, Angers, France 49933
Ph:+33241356329, E-mail: mathilde.moreau@chu-angers.fr
Notes
Shirazi 2012
Trial name or title A placebo-controlled clinical trial to assess efficacy of tranexamic acid in reducing haemorrhage after vaginal
delivery
Methods Randomised, not blinded, assignment - parallel.
Participants Women with term, singleton pregnancy candidate for the first vaginal delivery
Exclusion criteria - severe medical complications involving the heart, brain, kidney; allergy to tranexamic acid;
visual problems; severe pregnancy complications such as pre-eclampsia; thromboembolic events; placenta
abruption
Interventions Intervention group - 1 g tranexamic acid in 20 mL 5% dextrose IV soon after neonatal delivery
Control group - 20 mL 5% dextrose with 10 mL normal saline IV soon after neonatal delivery
Outcomes Primary outcomes - haemoglobin before and after delivery, need for transfusion, surgery, hysterectomy, death,
thrombotic events
Starting date 10 OCT 2012.
Contact information Dr Fereshteh Heidari Shirazi.
Shahid Beheshti Hospital 5th km of Ghotberavandi blvd. Kashan Iran Kashan
Isfahan
ISLAMIC REPUBLIC OF IRAN
87159/88141
hamiidi@yahoo.com
Notes
CS: caesarean section
IV: intravenously
PPH: postpartum haemorrhage
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D A T A A N D A N A L Y S E S
Comparison 1. Tranexamic acid versus placebo/no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss > 400 mL or > 500
mL
6 1398 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.42, 0.63]
1.1 Tranexamic acid in vaginal
birth
3 832 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.28, 0.63]
1.2 Tranexamic acid in
caesarean section
3 566 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.44, 0.69]
2 Blood loss > 1000 mL 6 2093 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.23, 0.71]
2.1 Tranexamic acid in vaginal
birth
2 559 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.06, 1.36]
2.2 Tranexamic acid in
caesarean section
4 1534 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.23, 0.78]
3 Mean blood loss (mL) 5 1186 Mean Difference (IV, Fixed, 95% CI) -77.79 [-97.95, -57.
64]
3.1 Tranexamic acid in vaginal
birth
3 832 Mean Difference (IV, Fixed, 95% CI) -80.56 [-104.80, -
56.33]
3.2 Tranexamic acid in
caesarean section
2 354 Mean Difference (IV, Fixed, 95% CI) -71.57 [-107.89, -
35.26]
4 Use of additional medical
interventions to control PPH
5 2049 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.34, 0.68]
4.1 Tranexamic acid in vaginal
birth
2 559 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.16, 0.72]
4.2 Tranexamic acid in
caesarean section
3 1490 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.36, 0.81]
5 Use of additional surgical
interventions to control PPH
4 2051 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.1 Tranexamic acid in vaginal
birth
1 439 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Tranexamic acid in
caesarean section
3 1612 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Blood transfusion 6 1698 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.11, 0.53]
6.1 Tranexamic acid in vaginal
birth
1 439 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.17]
6.2 Tranexamic acid in CS 5 1259 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.10, 0.54]
7 Maternal death or severe
maternal morbidity such as
seizure, thromboembolic
events, need for intensive care
unit admission, hysterectomy,
organ failure
4 1511 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.1 Tranexamic acid in vaginal
birth
2 559 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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7.2 Tranexamic acid in
caesarean section
2 952 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Side effects 8 2616 Risk Ratio (M-H, Random, 95% CI) 2.48 [1.36, 4.50]
8.1 Tranexamic acid in vaginal
birth
3 740 Risk Ratio (M-H, Random, 95% CI) 1.96 [1.50, 2.55]
8.2 Tranexamic acid in
caesarean section
5 1876 Risk Ratio (M-H, Random, 95% CI) 3.78 [0.69, 20.66]
9 Thromboembolic events 11 3012 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.14, 6.78]
9.1 Tranexamic acid in vaginal
birth
2 559 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Tranexamic acid for
caesarean section
9 2453 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.14, 6.78]
Comparison 2. Different doses of tranexamic acid
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss > 400 mL 1 186 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.19, 1.25]
2 Mean blood loss 2 246 Mean Difference (IV, Random, 95% CI) 58.86 [-54.82, 172.
54]
2.1 Tranexamic acid in vaginal
birth
1 186 Mean Difference (IV, Random, 95% CI) -0.40 [-41.06, 40.
26]
2.2 Tranexamic acid in CS 1 60 Mean Difference (IV, Random, 95% CI) 115.63 [92.31, 138.
95]
3 Use of additional medical
interventions to control PPH
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.27, 8.34]
4 Side effects 1 60 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 20.90]
5 Thromboembolic events 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 1 Blood loss > 400 mL
or > 500 mL.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 1 Tranexamic acid versus placebo/no treatment
Outcome: 1 Blood loss > 400 mL or > 500 mL
Study or subgroup TA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tranexamic acid in vaginal birth
Gungorduk 2013 4/220 15/219 3.4 % 0.27 [ 0.09, 0.79 ]
Mirghafourvand 2013 9/60 15/60 7.3 % 0.60 [ 0.28, 1.26 ]
Yang 2001 18/186 22/87 12.5 % 0.38 [ 0.22, 0.68 ]
Subtotal (95% CI) 466 366 23.2 % 0.42 [ 0.28, 0.63 ]
Total events: 31 (TA), 52 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.68, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 4.10 (P = 0.000041)
2 Tranexamic acid in caesarean section
Gai 2004 22/91 36/89 20.7 % 0.60 [ 0.38, 0.93 ]
Xu 2013 19/88 28/86 16.1 % 0.66 [ 0.40, 1.09 ]
Yehia 2014 33/106 67/106 40.0 % 0.49 [ 0.36, 0.68 ]
Subtotal (95% CI) 285 281 76.8 % 0.55 [ 0.44, 0.69 ]
Total events: 74 (TA), 131 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 5.07 (P < 0.00001)
Total (95% CI) 751 647 100.0 % 0.52 [ 0.42, 0.63 ]
Total events: 105 (TA), 183 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.14, df = 5 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 6.42 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.32, df = 1 (P = 0.25), I2 =24%
0.1 0.2 0.5 1 2 5 10
Favours TA Favours control
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Analysis 1.2. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 2 Blood loss > 1000
mL.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 1 Tranexamic acid versus placebo/no treatment
Outcome: 2 Blood loss > 1000 mL
Study or subgroup TA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tranexamic acid in vaginal birth
Gungorduk 2013 1/220 5/219 12.7 % 0.20 [ 0.02, 1.69 ]
Mirghafourvand 2013 1/60 2/60 5.1 % 0.50 [ 0.05, 5.37 ]
Subtotal (95% CI) 280 279 17.8 % 0.28 [ 0.06, 1.36 ]
Total events: 2 (TA), 7 (Control)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
2 Tranexamic acid in caesarean section
Abdel-Aleem 2013 2/373 2/367 5.1 % 0.98 [ 0.14, 6.95 ]
Goswami 2013 0/30 0/30 Not estimable
Gungorduk 2011 7/330 19/330 48.3 % 0.37 [ 0.16, 0.86 ]
Shahid 2013 5/38 11/36 28.7 % 0.43 [ 0.17, 1.12 ]
Subtotal (95% CI) 771 763 82.2 % 0.43 [ 0.23, 0.78 ]
Total events: 14 (TA), 32 (Control)
Heterogeneity: Chi2 = 0.82, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0058)
Total (95% CI) 1051 1042 100.0 % 0.40 [ 0.23, 0.71 ]
Total events: 16 (TA), 39 (Control)
Heterogeneity: Chi2 = 1.31, df = 4 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
0.01 0.1 1 10 100
Favours TA Favours control
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Analysis 1.3. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 3 Mean blood loss
(mL).
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 1 Tranexamic acid versus placebo/no treatment
Outcome: 3 Mean blood loss (mL)
Study or subgroup TA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Tranexamic acid in vaginal birth
Gungorduk 2013 220 261.5 (146.8) 219 349.98 (188.8) 40.6 % -88.48 [ -120.13, -56.83 ]
Mirghafourvand 2013 60 310.2 (188.7) 60 371.8 (243.7) 6.7 % -61.60 [ -139.59, 16.39 ]
Yang 2001 186 243.1 (140.4) 87 314.8 (180.9) 21.9 % -71.70 [ -114.74, -28.66 ]
Subtotal (95% CI) 466 366 69.2 % -80.56 [ -104.80, -56.33 ]
Heterogeneity: Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 6.52 (P < 0.00001)
2 Tranexamic acid in caesarean section
Gai 2004 91 359.3 (152) 89 439.4 (191.5) 15.9 % -80.10 [ -130.68, -29.52 ]
Xu 2013 88 379.2 (160.1) 86 441.7 (189.5) 14.9 % -62.50 [ -114.68, -10.32 ]
Subtotal (95% CI) 179 175 30.8 % -71.57 [ -107.89, -35.26 ]
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 3.86 (P = 0.00011)
Total (95% CI) 645 541 100.0 % -77.79 [ -97.95, -57.64 ]
Heterogeneity: Chi2 = 1.02, df = 4 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 7.56 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
-200 -100 0 100 200
Favours TA Favours control
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Analysis 1.4. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 4 Use of additional
medical interventions to control PPH.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 1 Tranexamic acid versus placebo/no treatment
Outcome: 4 Use of additional medical interventions to control PPH
Study or subgroup TA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tranexamic acid in vaginal birth
Gungorduk 2013 6/220 19/219 22.2 % 0.31 [ 0.13, 0.77 ]
Mirghafourvand 2013 3/60 7/60 8.2 % 0.43 [ 0.12, 1.58 ]
Subtotal (95% CI) 280 279 30.4 % 0.35 [ 0.16, 0.72 ]
Total events: 9 (TA), 26 (Control)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.82 (P = 0.0048)
2 Tranexamic acid in caesarean section
Abdel-Aleem 2013 1/373 1/367 1.2 % 0.98 [ 0.06, 15.67 ]
Goswami 2013 5/60 8/30 12.4 % 0.31 [ 0.11, 0.87 ]
Gungorduk 2011 28/330 48/330 56.0 % 0.58 [ 0.38, 0.91 ]
Subtotal (95% CI) 763 727 69.6 % 0.54 [ 0.36, 0.81 ]
Total events: 34 (TA), 57 (Control)
Heterogeneity: Chi2 = 1.39, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
Total (95% CI) 1043 1006 100.0 % 0.48 [ 0.34, 0.68 ]
Total events: 43 (TA), 83 (Control)
Heterogeneity: Chi2 = 2.56, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 4.09 (P = 0.000043)
Test for subgroup differences: Chi2 = 1.11, df = 1 (P = 0.29), I2 =10%
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Favours TA Favours control
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Analysis 1.5. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 5 Use of additional
surgical interventions to control PPH.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 1 Tranexamic acid versus placebo/no treatment
Outcome: 5 Use of additional surgical interventions to control PPH
Study or subgroup TA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tranexamic acid in vaginal birth
Gungorduk 2013 0/220 0/219 Not estimable
Subtotal (95% CI) 220 219 Not estimable
Total events: 0 (TA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Tranexamic acid in caesarean section
Abdel-Aleem 2013 0/373 0/367 Not estimable
Gungorduk 2011 0/330 0/330 Not estimable
Yehia 2014 0/106 0/106 Not estimable
Subtotal (95% CI) 809 803 Not estimable
Total events: 0 (TA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1029 1022 Not estimable
Total events: 0 (TA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.6. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 6 Blood transfusion.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 1 Tranexamic acid versus placebo/no treatment
Outcome: 6 Blood transfusion
Study or subgroup TA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tranexamic acid in vaginal birth
Gungorduk 2013 1/220 3/219 10.7 % 0.33 [ 0.03, 3.17 ]
Subtotal (95% CI) 220 219 10.7 % 0.33 [ 0.03, 3.17 ]
Total events: 1 (TA), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
2 Tranexamic acid in CS
Goswami 2013 0/60 2/30 11.8 % 0.10 [ 0.01, 2.05 ]
Gungorduk 2011 2/330 7/330 24.9 % 0.29 [ 0.06, 1.37 ]
Senturk 2013 0/101 0/122 Not estimable
Shahid 2013 3/38 12/36 43.8 % 0.24 [ 0.07, 0.77 ]
Yehia 2014 0/106 2/106 8.9 % 0.20 [ 0.01, 4.12 ]
Subtotal (95% CI) 635 624 89.3 % 0.23 [ 0.10, 0.54 ]
Total events: 5 (TA), 23 (Control)
Heterogeneity: Chi2 = 0.37, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00073)
Total (95% CI) 855 843 100.0 % 0.24 [ 0.11, 0.53 ]
Total events: 6 (TA), 26 (Control)
Heterogeneity: Chi2 = 0.46, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.50 (P = 0.00046)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
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Analysis 1.7. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 7 Maternal death or
severe maternal morbidity such as seizure, thromboembolic events, need for intensive care unit admission,
hysterectomy, organ failure.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 1 Tranexamic acid versus placebo/no treatment
Outcome: 7 Maternal death or severe maternal morbidity such as seizure, thromboembolic events, need for intensive care unit admission, hysterectomy, organ failure
Study or subgroup TA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tranexamic acid in vaginal birth
Gungorduk 2013 0/220 0/219 Not estimable
Mirghafourvand 2013 0/60 0/60 Not estimable
Subtotal (95% CI) 280 279 Not estimable
Total events: 0 (TA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Tranexamic acid in caesarean section
Abdel-Aleem 2013 0/373 0/367 Not estimable
Yehia 2014 0/106 0/106 Not estimable
Subtotal (95% CI) 479 473 Not estimable
Total events: 0 (TA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 759 752 Not estimable
Total events: 0 (TA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours TA Favours control
53Tranexamic acid for preventing postpartum haemorrhage (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 8 Side effects.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 1 Tranexamic acid versus placebo/no treatment
Outcome: 8 Side effects
Study or subgroup TA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tranexamic acid in vaginal birth
Gungorduk 2013 106/220 55/219 30.8 % 1.92 [ 1.47, 2.50 ]
Mirghafourvand 2013 4/60 0/60 3.8 % 9.00 [ 0.50, 163.58 ]
Yang 2001 2/94 0/87 3.5 % 4.63 [ 0.23, 95.14 ]
Subtotal (95% CI) 374 366 38.0 % 1.96 [ 1.50, 2.55 ]
Total events: 112 (TA), 55 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.43, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 4.97 (P < 0.00001)
2 Tranexamic acid in caesarean section
Abdel-Aleem 2013 277/373 195/367 32.4 % 1.40 [ 1.25, 1.57 ]
Goswami 2013 3/60 2/30 8.7 % 0.75 [ 0.13, 4.25 ]
Gungorduk 2011 53/330 0/330 4.0 % 107.00 [ 6.63, 1725.70 ]
Xu 2013 24/88 4/86 16.8 % 5.86 [ 2.12, 16.19 ]
Yehia 2014 0/106 0/106 Not estimable
Subtotal (95% CI) 957 919 62.0 % 3.78 [ 0.69, 20.66 ]
Total events: 357 (TA), 201 (Control)
Heterogeneity: Tau2 = 2.40; Chi2 = 29.02, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.53 (P = 0.12)
Total (95% CI) 1331 1285 100.0 % 2.48 [ 1.36, 4.50 ]
Total events: 469 (TA), 256 (Control)
Heterogeneity: Tau2 = 0.28; Chi2 = 35.09, df = 6 (P<0.00001); I2 =83%
Test for overall effect: Z = 2.97 (P = 0.0029)
Test for subgroup differences: Chi2 = 0.56, df = 1 (P = 0.45), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.9. Comparison 1 Tranexamic acid versus placebo/no treatment, Outcome 9 Thromboembolic
events.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 1 Tranexamic acid versus placebo/no treatment
Outcome: 9 Thromboembolic events
Study or subgroup TA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tranexamic acid in vaginal birth
Gungorduk 2013 0/220 0/219 Not estimable
Mirghafourvand 2013 0/60 0/60 Not estimable
Subtotal (95% CI) 280 279 Not estimable
Total events: 0 (TA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Tranexamic acid for caesarean section
Abdel-Aleem 2013 0/373 0/367 Not estimable
Gai 2004 0/91 0/89 Not estimable
Goswami 2013 0/60 0/30 Not estimable
Gungorduk 2011 0/330 0/330 Not estimable
Movafegh 2011 0/50 0/50 Not estimable
Senturk 2013 0/101 0/122 Not estimable
Shahid 2013 0/38 0/36 Not estimable
Xu 2013 2/88 2/86 100.0 % 0.98 [ 0.14, 6.78 ]
Yehia 2014 0/106 0/106 Not estimable
Subtotal (95% CI) 1237 1216 100.0 % 0.98 [ 0.14, 6.78 ]
Total events: 2 (TA), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 1517 1495 100.0 % 0.98 [ 0.14, 6.78 ]
Total events: 2 (TA), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Different doses of tranexamic acid, Outcome 1 Blood loss > 400 mL.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 2 Different doses of tranexamic acid
Outcome: 1 Blood loss > 400 mL
Study or subgroup 1 G TA 0.5 G TA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yang 2001 6/94 12/92 100.0 % 0.49 [ 0.19, 1.25 ]
Total (95% CI) 94 92 100.0 % 0.49 [ 0.19, 1.25 ]
Total events: 6 (1 G TA), 12 (0.5 G TA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Different doses of tranexamic acid, Outcome 2 Mean blood loss.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 2 Different doses of tranexamic acid
Outcome: 2 Mean blood loss
Study or subgroup
0.5 G or
10 mg/kg
TA 1 G or 15 mg/kg TA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Tranexamic acid in vaginal birth
Yang 2001 92 242.9 (168.9) 94 243.3 (106.3) 48.9 % -0.40 [ -41.06, 40.26 ]
Subtotal (95% CI) 92 94 48.9 % -0.40 [ -41.06, 40.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
2 Tranexamic acid in CS
Goswami 2013 30 376.83 (31.96) 30 261.2 (56.8) 51.1 % 115.63 [ 92.31, 138.95 ]
Subtotal (95% CI) 30 30 51.1 % 115.63 [ 92.31, 138.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.72 (P < 0.00001)
Total (95% CI) 122 124 100.0 % 58.86 [ -54.82, 172.54 ]
Heterogeneity: Tau2 = 6445.54; Chi2 = 23.54, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 23.54, df = 1 (P = 0.00), I2 =96%
-200 -100 0 100 200
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Analysis 2.3. Comparison 2 Different doses of tranexamic acid, Outcome 3 Use of additional medical
interventions to control PPH.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 2 Different doses of tranexamic acid
Outcome: 3 Use of additional medical interventions to control PPH
Study or subgroup 15 mg/ kg TA 10 mg/kg TA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goswami 2013 3/30 2/30 100.0 % 1.50 [ 0.27, 8.34 ]
Total (95% CI) 30 30 100.0 % 1.50 [ 0.27, 8.34 ]
Total events: 3 (15 mg/ kg TA), 2 (10 mg/kg TA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 1G or 15 mg/kg Favours 0.5G or 10 mg/kg
Analysis 2.4. Comparison 2 Different doses of tranexamic acid, Outcome 4 Side effects.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 2 Different doses of tranexamic acid
Outcome: 4 Side effects
Study or subgroup 1 G or 15 mg/kg 0.5 G or 10 mg/kg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goswami 2013 2/30 1/30 100.0 % 2.00 [ 0.19, 20.90 ]
Total (95% CI) 30 30 100.0 % 2.00 [ 0.19, 20.90 ]
Total events: 2 (1 G or 15 mg/kg), 1 (0.5 G or 10 mg/kg)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 1 g or 15 mg/kg T Favours 0.5G or 10 mg/kg
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Analysis 2.5. Comparison 2 Different doses of tranexamic acid, Outcome 5 Thromboembolic events.
Review: Tranexamic acid for preventing postpartum haemorrhage
Comparison: 2 Different doses of tranexamic acid
Outcome: 5 Thromboembolic events
Study or subgroup 15 mg/kg TA 10 mg/kg TA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goswami 2013 0/30 0/30 Not estimable
Total (95% CI) 30 30 Not estimable
Total events: 0 (15 mg/kg TA), 0 (10 mg/kg TA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 1G/15 mg/kg TA Favours 0.5G/10 mg/kg TA
A D D I T I O N A L T A B L E S
Table 1. Outcomes reported in included studies used in the analysis
Study/
Outcomes
PPH > 400
mL or 500
mL
PPH >
1000 mL
Mean
blood loss
Additional
medical in-
terven-
tions
Additional
surgical in-
tervention
Blood
transfu-
sion
Maternal
death and
other seri-
ous mater-
nal
outcomes
Side effects Throm-
boembolic
events
Abdel-
Aleem
2013
X X X X X X
Gai 2004 X X X
Goswami
2013
X X X X X
Gungor-
duk
2011
X X X X X X
Gungor-
duk
2013
X X X X X X X X X
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Table 1. Outcomes reported in included studies used in the analysis (Continued)
Mirghafour-
vand
2013
X X X X X X X
Movafegh
2011
X
Senturk
2013
X X
Shahid
2013
X X
Xu 2013 X X X X
Yang 2001 X X X
Yehia 2014 X X X X X X
PPH: postpartum haemorrhage
WH A T ’ S N E W
Last assessed as up-to-date: 28 January 2015.
Date Event Description
10 February 2015 New citation required and conclusions have changed Ten new trials incorporated. The review now includes a
total of 12 trials
The review’s conclusions have changed: the previous re-
view concluded that TA decreases postpartumblood loss
after vaginal birth and CS based on two RCTs of un-
clear quality which reported only a few outcomes. Fol-
lowing inclusion of ten studies the new conclusion has
changed to “TA (in addition to uterotonic medications)
decreases postpartum blood loss and prevents PPH fol-
lowing vaginal birth and CS in low-risk women. TA
is not associated with severe side effects. The evidence
suggests that TA should be considered as part of routine
management for prevention of PPH”. We have added
information in the methods section on how the trials
with multiple groups are handled. We have updated the
secondary outcomes (added blood transfusion, removed
haemoglobin < 6 G%). We have added a description of
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(Continued)
blood loss measurement in methods / outcomes section
A ’Summary of findings’ table has been incorporated for
this update
10 February 2015 New search has been performed Search updated. Methods updated. We identified 20
reports of 19 trials. We have added ten studies:
Abdel-Aleem 2013; Goswami 2013; Gungorduk 2011;
Gungorduk 2013; Mirghafourvand 2013; Movafegh
2011; Senturk 2013; Shahid 2013; Xu 2013; Yehia 2014
to the previously included two trials. Two trials are still
ongoing Farber 2013; Shirazi 2012.One trial is awaiting
classification Bhavana 2013. Sentilhes 2014 is a proto-
col of ongoing trial, Ahmed 2014 was published in ab-
stract form only and is lacking information for adequate
assessment at this stage. We have excluded four newly
identified trials (Gobbur 2011; Gohel 2007; Sekhavat
2009; Tarabrin 2012).
H I S T O R Y
Protocol first published: Issue 3, 2009
Review first published: Issue 7, 2010
Date Event Description
15 February 2011 New search has been performed Search updated. We identified and excluded three new trials Gobbur 2011;
Gohel 2007; Sekhavat 2009
C O N T R I B U T I O N S O F A U T H O R S
N Novikova participated in designing the review, and writing the protocol and review. She undertook the initial data analysis. GJ
Hofmeyr conceived the review, and provided guidance in designing the review. He also provided a clinical perspective, and performed
duplicate data extraction.
For the current update N Novikova assessed the new studies, extracted the data, prepared the review. GJ Hofmeyr reviewed the drafts
of the update. CAC performed the duplicate data extraction and reviewed the draft of the update.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Effective Care Research Unit, University of Witwatersrand, University of Fort Hare, South Africa, South Africa.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The methods text has been updated to reflect the latest Cochrane Handbook (Higgins 2011) and the current standard methods text
used by the Cochrane Pregnancy and Childbirth Group.
We have updated the outcomes being assessed in this review, e.g. we added blood transfusion to secondary outcomes instead of
haemoglobin below 6 g%.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antifibrinolytic Agents [∗administration & dosage]; Injections, Intravenous; Postpartum Hemorrhage [∗prevention & control]; Ran-
domized Controlled Trials as Topic; Tranexamic Acid [∗administration & dosage]
MeSH check words
Female; Humans; Pregnancy
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